Split (3)

train · 29.5k rows

FEATURE_phases list	FEATURE_enrollmentCount int64	FEATURE_allocation string	FEATURE_interventionModel string	FEATURE_primaryPurpose class label	FEATURE_masking class label	FEATURE_healthyVolunteers bool	FEATURE_sex class label	FEATURE_oversightHasDmc bool	FEATURE_briefSummary string	FEATURE_detailedDescription string	FEATURE_conditions string	FEATURE_conditionsKeywords string	FEATURE_protocolPdfText string	FEATURE_numArms int64	FEATURE_armDescriptions string	FEATURE_armGroupTypes list	FEATURE_numInterventions int64	FEATURE_interventionTypes list	FEATURE_interventionDescriptions string	FEATURE_interventionNames string	FEATURE_numLocations int64	FEATURE_locationDetails string	LABEL_ct_level_ade_population int64	LABEL_sum_dosing_errors int64	LABEL_dosing_error_rate float32	LABEL_wilson_label int64	METADATA_nctId string	METADATA_overallStatus class label	METADATA_completionDate date32	METADATA_startDate date32	METADATA_leadSponsorName string	METADATA_leadSponsorClass class label	METADATA_hasProtocol bool	METADATA_hasSap bool	METADATA_hasIcf bool	METADATA_protocolPdfLinks string	METADATA_count_Accidental overdose int64	METADATA_count_Drug administration error int64	METADATA_count_Incorrect dose administered int64	METADATA_count_Multiple drug overdose int64	METADATA_count_Overdose int64	METADATA_wilson_lower_bound float32
[ 5 ]	36	RANDOMIZED	PARALLEL	1PREVENTION	4QUADRUPLE	false	0ALL	false	The purpose of this study is to compare the vascular effects of two commonly used diabetes medications, rosiglitazone and glyburide in type 2 diabetic patients.	Rosiglitazone and glyburide are two commonly used diabetic medications that have both been shown to be effective in controlling blood glucose levels. Since they work in different ways, they may have different effects on the health of the blood vessels. This study will assess which medication is better at improving the ...	Type 2 Diabetes Mellitus	thiazolidinedione sulfonylurea endothelial function	null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: rosiglitazone intervention 2: glyburide	1	Saint Paul \| Minnesota \| United States \| -93.09327 \| 44.94441	36	0	0	0	NCT00123643	1COMPLETED	2005-12-01	2003-05-01	St. Paul Heart Clinic	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 2, 3 ]	40	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	This study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight gain.	This is an open label smoking cessation clinical trial of 25 mg naltrexone with 300 mg bupropion sustained-release (SR) in six male and fourteen female participants. This pilot study is being conducted to determine: * effect size estimates for smoking cessation and post-cessation weight gain, which will be used to com...	Smoking Nicotine Dependence	Tobacco Smoking Weight Weight perception Naltrexone Bupropion	null	2	arm 1: The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day). arm 2: The active com...	[ 1, 0 ]	2	[ 0, 0 ]	intervention 1: Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment. intervention 2: Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for ...	intervention 1: Naltrexone intervention 2: Bupropion	1	New Haven \| Connecticut \| United States \| -72.92816 \| 41.30815	40	0	0	0	NCT00129246	1COMPLETED	2005-12-01	2004-12-01	Yale University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 5 ]	99	RANDOMIZED	PARALLEL	1PREVENTION	2DOUBLE	false	0ALL	false	The objective of this pilot study is to evaluate the efficacy of treatment with montelukast as compared to placebo in the prevention of recurrence of acute Otitis media (AOM)	Otitis media (OM) is one of the most common childhood disorders requiring physician care and has been associated with an alarming rise in prevalence. Certain children are prone to recurrent episodes of acute Otitis media (RAOM) and/or the development of chronic Otitis media with effusion (COME). Because medical therapy...	Acute Otitis Media Otitis Media Ear Infection	Ear Infections Otitis Media	null	2	arm 1: Treatment with montelukast for 4 months (4 mg per day) arm 2: Treatment with placebo for 4 months	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: Montelukast intervention 2: Placebo	2	Bellevue \| Pennsylvania \| United States \| -80.05172 \| 40.49396 Pittsburgh \| Pennsylvania \| United States \| -79.99589 \| 40.44062	99	0	0	0	NCT00189462	1COMPLETED	2005-12-01	2004-03-01	Deborah Gentile	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	136	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The purpose of the study is to compare the overnight efficacy and plasma concentration-time profiles of armodafinil and PROVIGIL, after multiple doses, in patients with excessive sleepiness associated with chronic Shift Work Sleep Disorder (SWSD).	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL in Patients with Chronic Shift Work Sleep Disorder	Chronic Shift Work Sleep Disorder		null	5	arm 1: PROVIGIL 200 mg/day arm 2: Armodafinil 250 mg/day arm 3: Armodafinil 200 mg/day arm 4: Armodafinil 150 mg/day arm 5: Placebo	[ 0, 0, 0, 0, 2 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: PROVIGIL 200 mg/day intervention 2: Armodafinil 250 mg/day intervention 3: Armodafinil 200 mg/day intervention 4: Armodafinil 150 mg/day intervention 5: Matching placebo tablets	intervention 1: PROVIGIL 200 mg intervention 2: Armodafinil 250 mg intervention 3: Armodafinil 200 mg intervention 4: Armodafinil 150 mg intervention 5: Placebo	20	Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Hot Springs \| Arkansas \| United States \| -93.05518 \| 34.5037 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 San Diego \| California \| United States \| -117.16472 \| 32.71571 San Diego \| Cali...	134	0	0	0	NCT00236080	1COMPLETED	2005-12-01	2005-08-01	Cephalon	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	224	RANDOMIZED	PARALLEL	9OTHER	0NONE	false	0ALL	null	To assess the change in hemoglobin levels when iron sucrose was added to a regimen of weekly, fixed doses of erythropoietin in patients who had or had not responded to erythropoietin therapy alone.	This was a two stage, randomized, controlled study of cancer patients undergoing or planning to undergo chemotherapy. After stage one, (where patients were exposed to an erythropoiesis stimulating agent), patients were randomized to receive either IV iron sucrose or no iron supplementation. Patients were then followed ...	Anemia	Anemia Cancer Chemotherapy	null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 1, 1, 1, 1 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: iron sucrose injection USP intervention 2: stable erythropoietin therapy	0	null	224	0	0	0	NCT00236951	1COMPLETED	2005-12-01	2003-02-01	American Regent, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	151	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	1FEMALE	null	Purpose of the study is the comparative evaluation of the clinical efficacy and of the general tolerability of two different subcutaneous FSH preparations (Fostimon® IBSA Vs Gonal-F® Serono) when administered in patients undergoing ICSI	This is a multicentric, prospective, randomised, investigator blind, controlled clinical trial (phase III) of two parallel groups, one receiving the test drug FSH (Fostimon® , IBSA) and the other the reference drug FSH (Gonal-F®, Serono). The groups will be paired on the major prognostic criteria. In effect, a double ...	Infertility	Ovarian stimulation Infertility ICSI FSH	null	2	arm 1: Fostimon is an highly purified FSH preparation. arm 2: Gonal-F is a recombinant FSH preparation.	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: subcutaneous injection of FSH. Starting dose: 225 IU. intervention 2: subcutaneous injection of FSH. Starting dose: 225 IU.	intervention 1: Follicle Stimulating Hormone intervention 2: Follicle Stimulating Hormone	7	Bron \| N/A \| France \| 4.91303 \| 45.73865 Lille \| N/A \| France \| 3.05858 \| 50.63297 Lyon \| N/A \| France \| 4.84671 \| 45.74846 Marseille \| N/A \| France \| 5.38107 \| 43.29695 Neuilly-sur-Seine \| N/A \| France \| 2.26965 \| 48.8846 Paris \| N/A \| France \| 2.3488 \| 48.85341 Budapest \| N/A \| Hungary \| 19.04045 \| 47.49835	145	0	0	0	NCT00335725	1COMPLETED	2005-12-01	2003-03-01	IBSA Institut Biochimique SA	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	37	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This 6-month open label study will evaluate the long term safety of bosentan (via oxygen saturation) and efficacy (exercise capacity) in patients who have completed the BREATHE-5 study (PAH related to Eisenmenger physiology). Treatment duration is 6 months.	This is a multicenter, open-label, single -arm study with bosentan, initial dose of 62.5 mg b.i.d., with a target dose of 125 mg b.i.d. All patients will be assessed for eligibility during the baseline visit (same as Week 16, end of study BREATHE-5 visit), and will have the option to enter into the open-label extension...	Pulmonary Arterial Hypertension	bosentan PAH related to Eisenmenger physiology Tracleer	null	1	arm 1: The starting dose for all patients will be 62.5 mg b.i.d. At the Week 4 visit, patients who were started on 62.5 mg b.i.d. will be uptitrated to 125 mg b.i.d. if the 62.5 mg b.i.d. dose was well-tolerated.	[ 0 ]	1	[ 0 ]	intervention 1: Patients will receive up to 125 mg b.i.d. of Tracleer.	intervention 1: Tracleer®	17	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Houston \| Texas \| United States \| -95.36327 \| 29.76328 Camperdown \| N/A \| Australia \| 151.17642 \| -33.88965 Victoria \| N/A \| Australia \| N/A \| N/A Vienna \| N/A \| Austria \| 16.37208 \| 48.20849 Leuven \| N/A \| Belgium \| 4.70093 \| 50.87959 Calgary \| Alberta \| Ca...	37	0	0	0	NCT00367770	1COMPLETED	2005-12-01	2004-01-01	Actelion	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	114	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This is a randomized, double-blind, multicenter clinical phase III study involving about 105 cancer patients aged \>18 years who are receiving palliative chemotherapy and who are suffering from chemotherapy associated anemia. A standard treatment group (ERYPO®) will be included to provide a reference reflecting current...	Eligible patients were randomized to one of two different treatment groups (EPO HEXAL or ERYPO) in a 2:1 ratio. Patients received double-blind treatment for a period of 12 weeks. Following randomization the patients were treated subcutaneously with a dose of 150 IU/kg body weight of study drug three times per week. Dos...	Anemia	Chemotherapy associated anemia in cancer patients	null	2	arm 1: HX575 (erythropoietin alfa of the Sponsor Hexal AG). Eligible patients to be randomized in ratio 2:1 and to be subcutaneously treated (solution for injection (s.c.)) for 12 weeks with HX575 in pre-filled syringes. The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the the...	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 1000, 2000, 4000, 8000 and 10.000 IU of rh erythropoiethin intervention 2: 1000, 2000, 4000, 8000 and 10.000 IU of epoetin alfa	intervention 1: HX575, solution for injection (s.c.) intervention 2: ERYPO®, Janssen-Cilag, solution for injection (s.c.)	19	Augsburg \| N/A \| Germany \| 10.89851 \| 48.37154 Bad Soden \| N/A \| Germany \| 9.36404 \| 50.28857 Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Freiburg im Breisgau \| N/A \| Germany \| 7.85222 \| 47.9959 Luckenwalde \| N/A \| Germany \| 13.1...	114	0	0	0	NCT00711958	1COMPLETED	2005-12-01	2004-11-01	Sandoz	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	22	RANDOMIZED	CROSSOVER	7BASIC_SCIENCE	0NONE	true	0ALL	false	The purpose of this study is to evaluate and compare the relative bioavailability of Quinine Sulfate capsules following a single, oral dose in healthy volunteers under fasting and fed conditions.	The purpose of this study is to evaluate and compare the relative bioavailability of Quinine Sulfate capsules following a single, oral dose in healthy volunteers under fasting and fed conditions. Twenty-two healthy, non-smoking, non-obese, male and female volunteers between the ages of 18 and 45 years of age will be r...	Healthy	Bioavailability	null	2	arm 1: A single dose of Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours. arm 2: A single dose of Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours. intervention 2: Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.	intervention 1: Quinine Sulfate 2 x 324 mg Capsules intervention 2: Quinine Sulfate 2 x 324 mg Capsules	0	null	44	0	0	0	NCT00726414	1COMPLETED	2005-12-01	2005-12-01	Mutual Pharmaceutical Company, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	351	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	This study was conducted to see if mometasone nasal spray is efficaceous for the treatment of perennial allergic rhinitis. Patients will be randomized to active mometasone, placebo mometasone, active fluticasone, or placebo fluticasone.	null	Perennial Allergic Rhinitis		null	4	arm 1: Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray arm 2: Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray arm 3: Mometasone furoate nasal spray 200 μg/day(QD) arm 4: Fluticasone Propionate...	[ 2, 2, 0, 1 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks intervention 2: Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take...	intervention 1: Placebo for MF intervention 2: Placebo for FP intervention 3: Mometasone intervention 4: Fluticasone	0	null	351	0	0	0	NCT00783224	1COMPLETED	2005-12-01	2005-09-01	Organon and Co	4INDUSTRY	false	false	false	null	0	0	0	0	0	-0
[ 4 ]	31	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	null	This was a prospective, open, non-comparative study to evaluate the safety and efficacy of recombinant human luteinizing hormone (rhLH, Luveris) administered subcutaneously (s.c.) in follicular development during ovulation induction in 31 Chinese female subjects with hypogonadotropic hypogonadism.	The objective of this prospective, open, non-comparative study was to assess the safety and efficacy of rhLH (Luveris) administered subcutaneously in follicular development during ovulation induction in Chinese female subjects with hypogonadotropic hypogonadism. The study was organized on an outpatient basis involving ...	Hypogonadism	Hypogonadism Recombinant human follicle stimulating hormone (r-hFSH) Recombinant leutinizing hormone (r-hLH)	null	0	null	null	3	[ 0, 0, 0 ]	intervention 1: One r-hLH (75 International Units \[IU\]) injection s.c. once daily. intervention 2: One r-hFSH (150 IU) injection s.c. once daily. intervention 3: After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU hCG.	intervention 1: Recombinant human luteinizing hormone (r-hLH) intervention 2: Recombinant human follicle-stimulating hormone (r-hFSH) intervention 3: Human chorionic gonadotropin (hCG)	1	Beijing \| N/A \| China \| 116.39723 \| 39.9075	31	0	0	0	NCT01084265	1COMPLETED	2005-12-01	2004-02-01	Merck KGaA, Darmstadt, Germany	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	337	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study was to assess the efficacy of Sativex in relieving symptoms of spasticity in multiple sclerosis	This was a 15 week (one week baseline and fourteen weeks treatment period), multicentre, double blind, randomised, placebo controlled, parallel group study to evaluate the efficacy of Sativex in subjects with symptoms of spasticity due to multiple sclerosis. Eligible subjects entered a seven day baseline period. Subjec...	Multiple Sclerosis		null	2	arm 1: Active treatment arm 2: Control	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Contains delta-9-tetrahydrocannabinol (THC) (27mg/ml): cannabidiol (CBD) (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg:CBD 60 mg) in 24 hours. intervent...	intervention 1: Sativex intervention 2: Placebo	1	Reading \| N/A \| United Kingdom \| -0.97113 \| 51.45625	337	0	0	0	NCT01599234	1COMPLETED	2005-12-01	2005-03-01	Jazz Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	267	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension	null	Pulmonary Hypertension		null	0	null	null	1	[ 0 ]	intervention 1: None	intervention 1: Sildenafil citrate	52	La Jolla \| California \| United States \| -117.2742 \| 32.84727 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 San Diego \| California \| United States \| -117.16472 \| 32.71571 Torrance \| California \| United States \| -118.34063 \| 33.83585 Torr...	265	4	0.015094	1	NCT00159861	1COMPLETED	2006-01-01	2003-07-01	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	4INDUSTRY	false	false	false	null	2	0	1	0	1	0.005885
[ 3 ]	195	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	The purpose of this study is to determine whether Xyrem (sodium oxybate) is effective when used alone to treat the pain and sleep disturbances of fibromyalgia.	Fibromyalgia affects millions of Americans, yet there are no FDA approved drugs to treat this debilitating condition. Besides causing pain, it also disrupts normal sleep patterns in many of its victims. Pain and lack of sleep reinforce each other, making patients progressively more miserable. Xyrem is a potent hypnotic...	Fibromyalgia	Fibromyalgia Pain	null	3	arm 1: Sodium oxybate 6.0 g per day. arm 2: Placebo (one of two doses matching active treatment by volume). arm 3: Sodium oxybate 4.5 g per day.	[ 0, 2, 0 ]	3	[ 0, 0, 0 ]	intervention 1: Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks. intervention 2: Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks. in...	intervention 1: Xyrem (sodium oxybate) oral solution intervention 2: Xyrem (sodium oxybate) oral solution intervention 3: Placebo	20	Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Beverly Hills \| California \| United States \| -118.40036 \| 34.07362 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Miami \| Florida \| United States \| -80.19366 \| 25.77427 West Palm Beach \| Florida \| United States \| -80.05337 \| 26.71534 Lexingt...	192	0	0	0	NCT00087555	1COMPLETED	2006-01-01	2004-07-01	Jazz Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	685	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to evaluate the clinical and microbial efficacy and safety of AzaSite compared to vehicle for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned to receive either 1.0 %...	null	Bacterial Conjunctivitis	Bacterial Conjunctivitis Pink Eye Conjunctivitis Eye Infection Eye Discharge	null	2	arm 1: None arm 2: None	[ 0, 3 ]	2	[ 0, 10 ]	intervention 1: 1.0% AzaSite contains 1.0% azithromycin, sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. AzaSite was prescribed as a single topical drop to the infected ...	intervention 1: AzaSite intervention 2: Vehicle	32	Flagstaff \| Arizona \| United States \| -111.65127 \| 35.19807 Cudahy \| California \| United States \| -118.18535 \| 33.96057 Petaluma and Santa Rosa \| California \| United States \| N/A \| N/A San Diego \| California \| United States \| -117.16472 \| 32.71571 Wheat Ridge \| Colorado \| United States \| -105.07721 \| 39.7661 Waterbury ...	683	0	0	0	NCT00105534	1COMPLETED	2006-01-01	2004-07-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	122	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This drug is being developed to treat cardiac edema. The primary purpose of this study is to investigate the dose response for body weight in seven-day repeated oral administration of OPC-41061 at 15, 30, and 45 mg or placebo in patients with extracellular volume expansion secondary to CHF despite taking furosemide at ...	null	Heart Failure, Congestive Edema	OPC-41061 Tolvaptan Heart Failure Edema Extracellular volume expansion	null	0	null	null	1	[ 0 ]	intervention 1: None	intervention 1: OPC-41061(Tolvaptan)	1	Tokyo \| N/A \| Japan \| 139.69171 \| 35.6895	118	0	0	0	NCT00234104	1COMPLETED	2006-01-01	2004-08-01	Otsuka Pharmaceutical Co., Ltd.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	478	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This is a double-blind, randomized, multicenter, parallel-group, equivalence study involving about 462 clinically stable hemodialysis patients aged 18 years or above suffering from anemia and treated previously with a stable dose of ERYPO® intravenously.	The primary objective of this Phase III study is the evaluation of therapeutic equivalence of HX575 Hexal AG and a comparator of epoetin alfa, ERYPO® in the maintenance intravenous treatment of renal anemia. Efficacy, dosage and safety of HX575 Hexal AG in the long-term treatment were assessed.	Anemia	Treatment of anemia in hemodialysis patients	null	2	arm 1: Eligible patients were switched from the comparator ERYPO®, to epoetin alfa HX575 Hexal AG in ratio 2:1 to be intravenously treated with HX575 in pre-filled syringes for 24 weeks (solution for injection i.v.). The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels be...	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin intervention 2: Solution for i.v. injection	intervention 1: HX575 epoetin alfa Hexal AG intervention 2: ERYPO®, Janssen-Cilag	54	Feldkirch \| N/A \| Austria \| 9.6 \| 47.23306 Graz \| N/A \| Austria \| 15.45 \| 47.06667 Graz \| N/A \| Austria \| 15.45 \| 47.06667 Graz \| N/A \| Austria \| 15.45 \| 47.06667 Innsbruck \| N/A \| Austria \| 11.39454 \| 47.26266 Sankt Pölten \| N/A \| Austria \| 15.63333 \| 48.2 Vienna \| N/A \| Austria \| 16.37208 \| 48.20849 Vienna \| N/A \| Au...	478	0	0	0	NCT00666835	1COMPLETED	2006-01-01	2004-04-01	Sandoz	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	45	RANDOMIZED	PARALLEL	null	2DOUBLE	true	0ALL	false	This study is a multiple ascending dose study to Assess the Safety, Tolerability, and Pharmacokinetics of orally dosed PG 760564 Administered Twice Daily to Healthy Male and Female Volunteers for 14 Days (27 Doses).	This study is a multiple ascending dose study to Assess the Safety, Tolerability, and Pharmacokinetics of orally dosed PG 760564 Administered Twice Daily to Healthy Male and Female Volunteers for 14 Days (27 Doses). The study is a multiple rising dose (MRD) study of active drug vs. placebo.	Healthy	Pharmacokinetics	null	5	arm 1: placebo capsule arm 2: 50 mg PG 760564 active arm 3: 100 mg PG 760564 active arm 4: 200 mg PG 760564 active arm 5: 400 mg PG 760564 active	[ 2, 0, 0, 0, 0 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: oral capsule, 2x/day for 14 days intervention 2: oral capsule, 50 mg, 2x/day for 14 days intervention 3: oral capsule, 100mg, 2x/day for 14 days intervention 4: oral capsule, 200 mg, 2x/day for 14 days intervention 5: oral capsule, 400 mg, 2x/day for 14 days	intervention 1: Placebo intervention 2: PG-760564 intervention 3: PG-760564 intervention 4: PG-760564 intervention 5: PG-760564	1	Miami \| Florida \| United States \| -80.19366 \| 25.77427	45	0	0	0	NCT00791388	1COMPLETED	2006-01-01	2005-08-01	Procter and Gamble	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	10	RANDOMIZED	CROSSOVER	null	0NONE	true	0ALL	false	Half the group will be given a high fat diet and the other half will fast. They will then be crossed over.	A food-effect study which will be conducted at any time during the MRD study period on one single cohort of subjects using 200 mg oral dose of PG 760564. Half the group will be given a high fat diet and the other half will fast. They will ten be crossed over.	Healthy	pharmacokinetics study	null	2	arm 1: 200 mg PG 760564, Subjects Fasted, single dose arm 2: 200 mg PG 760564, Subjects Fed high fat meal	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: 200 mg capsule, single dose,fasted when dosed, duration is 4 days intervention 2: 200 mg capsule, single dose,high fat diet when dosed, duration is 4 days	intervention 1: PG-760564 intervention 2: PG-760564	1	Miami \| Florida \| United States \| -80.19366 \| 25.77427	20	0	0	0	NCT00791817	1COMPLETED	2006-01-01	2005-08-01	Procter and Gamble	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	188	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	true	0ALL	null	This 5-part study will evaluate the safety, tolerability, and pharmacokinetics of two formulations of MK-0517 (with and without polysorbate 80) and aprepitant in healthy adults. Parts I to IV of this study will examine different doses of MK-0517 as well as two different formulations of MK-0517 (with and without polysor...	null	Chemotherapy-Induced Nausea and Vomiting Postoperative Nausea and Vomiting		null	14	arm 1: 100 mg MK-0517 (nonpolysorbate 80 formulation \[non-PS80\]) or placebo → 150 mg MK-0517 (non- PS80) or placebo → 125 mg aprepitant arm 2: 100 mg MK-0517 (PS80 formulation \[PS80\]) or placebo → 150 mg MK-0517 (PS80) or placebo → 125 mg aprepitant arm 3: 40 mg MK-0517 (non-PS80) or placebo → 40 mg aprepitant arm ...	[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]	12	[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]	intervention 1: MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes intervention 2: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes intervention 3: MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral ...	intervention 1: 90 mg MK-0517 (PS80) intervention 2: 100 mg MK-0517 (PS80) intervention 3: 100 MK-0517 (PS80) + 2 mg midazolam intervention 4: 115 mg MK-0517 (PS80) intervention 5: 150 mg MK-0517 (PS80) intervention 6: 40 mg MK-0517 (non-PS80) intervention 7: 100 mg MK-0517 (non-PS80) intervention 8: 150 mg MK-0517 (No...	0	null	424	0	0	0	NCT00990821	1COMPLETED	2006-01-01	2005-01-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	11	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	This study will assess whether daclizumab impairs the ability of children receiving a kidney transplant to elicit a primary immune response. The anticipated time on study treatment is 1 day, and the target sample size is 82 individuals.	null	Kidney Transplantation		null	2	arm 1: Participants who were receiving a full course of 5 doses of daclizumab (1 milligram per kilogram \[mg/kg\]) with Day 1 vaccine administered immediately prior to the fifth dose. arm 2: Participants who completed a full course of daclizumab therapy in the previous 4 to 18 months.	[ 0, 1 ]	3	[ 2, 0, 2 ]	intervention 1: Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show \>=1.5 fold increase in lymphocyte proliferative response but have a humoral response. intervention 2...	intervention 1: DT intervention 2: Daclizumab intervention 3: KLH	5	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838 Kansas City \| Missouri \| United States \| -94.57857 \| 39.09973 Portland \| Oregon \| United States \| -122.67621 \| 45.52345	11	0	0	0	NCT02576145	1COMPLETED	2006-01-01	2003-04-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	152	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Study will assess efficacy, safety and tolerability of brivaracetam in post-herpetic neuralgia (PHN). Duration of 7 weeks divided into 3 periods with no up-titration, nor down-titration.	null	Neuralgia, Postherpetic	Post-herpetic Neuralgia (PHN) Brivaracetam	null	3	arm 1: Matching placebo tablets administered twice a day. arm 2: Brivaracetam 200 mg/day (100 mg administered twice a day). arm 3: Brivaracetam 400 mg/day (200 mg administered twice a day).	[ 2, 0, 0 ]	2	[ 0, 0 ]	intervention 1: Daily oral dose of two equal intakes. intervention 2: Daily oral dose of two equal intakes.	intervention 1: Placebo intervention 2: Brivaracetam	50	Brussels \| N/A \| Belgium \| 4.34878 \| 50.85045 Eeklo \| N/A \| Belgium \| 3.55654 \| 51.18703 Genk \| N/A \| Belgium \| 5.50082 \| 50.965 Liège \| N/A \| Belgium \| 5.56749 \| 50.63373 Lubbeek (Pellenberg) \| N/A \| Belgium \| 4.83896 \| 50.88278 Pleven \| N/A \| Bulgaria \| 24.61667 \| 43.41667 Sofia \| N/A \| Bulgaria \| 23.32415 \| 42.69751...	152	0	0	0	NCT00160667	1COMPLETED	2006-01-05	2004-10-11	UCB Pharma	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	73	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	true	0ALL	false	Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.	null	Infections, Herpesviridae	viral shedding Recurrent herpes genital herpes	null	2	arm 1: VALTREX 1 g once daily, Placebo arm 2: Placebo, VALTREX 1 g once daily	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Valtrex 1g once daily intervention 2: placebo	intervention 1: Valaciclovir intervention 2: Placebo	17	Carmichael \| California \| United States \| -121.32828 \| 38.61713 Davis \| California \| United States \| -121.74052 \| 38.54491 Riverside \| California \| United States \| -117.39616 \| 33.95335 Sacramento \| California \| United States \| -121.4944 \| 38.58157 Fort Wayne \| Indiana \| United States \| -85.12886 \| 41.1306 Indianapolis...	128	0	0	0	NCT00116844	1COMPLETED	2006-01-10	2005-03-29	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	946	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	1FEMALE	false	To investigate efficacy and safety of 4 doses of esmirtazapine, compared to placebo, in the treatment of moderate to severe hot flushes (vasomotor symptoms) associated with the menopause. Co-primary efficacy endpoints are the frequency and severity of hot flushes after 4 and 12 weeks as compared to Baseline.	The most direct treatment of hot flushes may be by means of 5-HT2A receptor antagonist. Mirtazapine is a potent blocker of 5-HT2A receptors and was found to be effective in reducing the number and intensity of hot flushes in preliminary trials. Also several Selective Serotonin Reuptake Inhibitors (SSRIs) and other simi...	Postmenopausal Symptoms Menopause Vasomotor Symptoms		null	5	arm 1: Participants receive encapsulated tablets, orally, once daily (QD) for up to 12 weeks. arm 2: Participants receive esmirtazapine, 2.25 mg, encapsulated tablets, orally QD for up to 12 weeks. arm 3: Participants receive esmirtazapine, 4.5 mg, encapsulated tablets, orally QD for up to 12 weeks. arm 4: Participants...	[ 2, 0, 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks. intervention 2: Encapsulated placebo tablets in Swe...	intervention 1: Esmirtazapine intervention 2: Placebo	0	null	945	0	0	0	NCT00535288	1COMPLETED	2006-01-15	2004-09-15	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	943	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	1FEMALE	false	The most direct treatment of vasomotor symptions (hot flushes) may be by means of 5-HT2A receptor antagonist. Mirtazapine is a potent blocker of 5-HT2A receptors and was found to be effective in reducing the number and intensity of hot flushes in preliminary trials. Also several Selective Serotonin Reuptake Inhibitors ...	null	Menopause Vasomotor Symptoms		null	5	arm 1: Participants receive placebo, encapsulated tablets, orally (PO), once daily (QD) for up to 12 weeks arm 2: Participants receive esmirtazapine 2.25 mg, encapsulated tablets, PO, QD for up to 12 weeks arm 3: Participants receive esmirtazapine 4.5 mg, encapsulated tablets, PO, QD for up to 12 weeks arm 4: Participa...	[ 2, 0, 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: esmirtazapine intervention 2: Placebo	0	null	941	0	0	0	NCT00560833	1COMPLETED	2006-01-15	2004-10-15	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	166	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	null	Clinical validation of the assisted reproductive technology (ART) treatment guidelines, which determine the optimal dose of recombinant human follicle stimulating hormone (r-hFSH) based on subject baseline characteristics/predictors of ovarian response.	null	Infertility	Assisted Reproductive Technology (ART) Infertility Ovarian stimulation	null	8	arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None arm 7: None arm 8: None	[ 0, 0, 0, 0, 0, 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle. intervention 2: When at least 1 follicle greater than or eq...	intervention 1: Gonal-f intervention 2: Recombinant human chorionic gonadotrophin (r-hCG)	1	Paris \| N/A \| France \| 2.3488 \| 48.85341	161	0	0	0	NCT00249834	1COMPLETED	2006-01-16	2004-09-22	Merck KGaA, Darmstadt, Germany	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	223	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until Levetiracetam (Keppra®) is approved for use in children or until the completion of the development program for pediatrics...	null	Epilepsy, Partial	Epilepsy Pediatric Partial onset epilepsy Levetiracetam Keppra	null	4	arm 1: Subjects had previously participated in study N159 in which they had received Placebo (PBO). arm 2: Subjects had previously participated in study N159 in which they had received Levetiracetam (LEV). arm 3: Subjects had previously participated in study N01010 or study N151 in which they had received Levetiracetam...	[ 0, 0, 0, 0 ]	1	[ 0 ]	intervention 1: * Pharmaceutical form: Oral tablets and oral solution * Route of administration: Oral use	intervention 1: Levetiracetam	0	null	223	2	0.008969	1	NCT00150709	1COMPLETED	2006-01-25	1998-01-26	UCB Pharma	4INDUSTRY	false	false	false	null	0	0	0	0	2	0.002463
[ 3 ]	104	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The purpose of this study is to exploratively investigate the clinical efficacy of rebamipide on dry mouth in patients with Sjögren's syndrome in comparison with placebo.	null	Xerostomia Sjogren's Syndrome		null	0	null	null	1	[ 0 ]	intervention 1: None	intervention 1: Rebamipide	1	Tokyo \| N/A \| Japan \| 139.69171 \| 35.6895	104	0	0	0	NCT00233363	1COMPLETED	2006-01-27	2005-04-15	Otsuka Pharmaceutical Co., Ltd.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	81	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This study will use a randomized, double-blind, controlled trial design in order to assess the safety and efficacy of levalbuterol (LEV) compared to racemic albuterol (RAC) when delivered continuously in a high-dose regimen for children with severe exacerbations of asthma. Primary hypothesis * Children with severe as...	High-dose nebulized albuterol is standard therapy for severe asthma exacerbations at The Children's Hospital of Philadelphia (CHOP) and other tertiary care pediatric hospitals throughout the United States. For the most severe exacerbations, albuterol is provided continuously at high doses until improvement is observed....	Asthma	Asthma Levalbuterol Albuterol Children	null	2	arm 1: Nebulized levalbuterol 10mg/hr given continuously arm 2: Racemic albuterol 20mg/hr given continuously	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 20mg/hr continuous racemic albuterol intervention 2: 10mg/hr continuous nebulized levalbuterol	intervention 1: Racemic albuterol (R+S albuterol) intervention 2: Levalbuterol (R albuterol)	1	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	81	0	0	0	NCT00124176	1COMPLETED	2006-02-01	2004-04-01	Children's Hospital of Philadelphia	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	172	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	Multicenter, randomized, double-blind, placebo-controlled, 5-arm, dose-ranging study to assess the efficacy of subcutaneous injections of Golimumab (CNTO 148), 50 or 100 mg, at either 2- or 4- week intervals in subjects with active RA despite MTX therapy.	This is an experimental medical research study. The purpose of this study is to determine if Golimumab is safe and effective in the treatment of rheumatoid arthritis. Subjects will receive subcutaneous injections of either 50 or 100 mg Golimumab or placebo every two or four weeks or an infusion of infliximab at week 2...	Rheumatoid Arthritis	Rheumatoid Arthritis CNTO 148 Methotrexate Joint pain Arthritis	null	3	arm 1: None arm 2: None arm 3: None	[ 0, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Type=exact, unit=mg/ml, number= 50 to 100 , form=powder for solution for infusion, route=sub cutaneous. intervention 2: Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous intervention 3: Type=exact, unit=mg/ml, form=powder for solution for infusion, route=sub ...	intervention 1: Golimumab intervention 2: MTX intervention 3: Placebo intervention 4: Infliximab	0	null	171	0	0	0	NCT00207714	1COMPLETED	2006-02-01	2003-11-01	Centocor, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	124	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory distress syndrome(ARDS).	This is a multinational, multicenter, two-part, Phase 2 study that will evaluate the tolerability, safety, and efficacy of KL₄Surfactant in adult ARDS patients when administered by sequential bronchoscopic lavage into each of the 19 bronchopulmonary segments of the lung and as a bolus instillation into each lung.	Acute Respiratory Distress Syndrome		null	7	arm 1: 3 30-mL aliquots per bronchopulmonary segment using concentrations of 5, 5, and 10 mg/mL total phopholipids. One re-treatment at 48 hours. arm 2: 3 30-mL aliquots per bronchopulmonary segment using concentrations of 10, 10, and 10 mg/mL total phospholipids. One lavage re-treatment at 48 hours. arm 3: 2 50-mL ali...	[ 0, 0, 0, 0, 0, 0, 5 ]	7	[ 0, 10, 0, 0, 0, 0, 0 ]	intervention 1: 3 30 mL aliquots at concentrations of 5, 5, and 10 mg/mL intervention 2: Standard ARDS management and ICU care intervention 3: 3 30 mL aliquots at a concentration of 10 mg/mL each intervention 4: 2 50 mL aliquots at concentrations of 10 and 20 mg/mL intervention 5: 2 50 mL aliquots at concentrations of ...	intervention 1: A.1 Lucinactant intervention 2: B.3 SoC intervention 3: A.2 Lucinactant intervention 4: A.3 Lucinactant intervention 5: A.4 Lucinactant intervention 6: B.1 Lucinactant intervention 7: B.2 Lucinactant	1	Warrington \| Pennsylvania \| United States \| -75.13406 \| 40.24927	124	0	0	0	NCT00215553	6TERMINATED	2006-02-01	2001-05-01	Windtree Therapeutics	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	39	RANDOMIZED	CROSSOVER	0TREATMENT	1SINGLE	false	0ALL	false	This is a Phase 3, single-dose, investigator-blind, randomized, placebo-controlled, crossover study, conducted at a single site in Austria, outside of the normal grass pollen season. An allergic reaction will be induced by exposing subjects to grass pollen in the Vienna Challenge Chamber (VCC). Subjects will receive a ...	null	Rhinitis, Allergic, Seasonal		null	6	arm 1: Phenylephrine: Immediate-release 12 mg capsules for oral administration. Pseudoephedrine: 60 mg immediate-release tablets for oral administration. Placebo: Placebo capsules. arm 2: Pseudoephedrine: 60 mg immediate-release tablets for oral administration. Placebo: Placebo capsules. Phenylephrine: Immediate-re...	[ 0, 0, 0, 0, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: immediate-release 12 mg capsules for oral administration intervention 2: 60 mg immediate-release tablets for oral administration intervention 3: placebo capsules	intervention 1: phenylephrine intervention 2: pseudoephedrine intervention 3: placebo	0	null	117	0	0	0	NCT00276016	1COMPLETED	2006-02-01	2006-01-01	Organon and Co	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	361	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	false	This study compares the safety and efficacy of intravenous iron vs oral iron in subjects who display postpartum anemia.	This is an open label, Phase III, randomized, active controlled study of intravenous iron vs oral iron in anemic post partum patients.	Anemia	Anemia postpartum Postpartum anemia	null	2	arm 1: A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered arm 2: 325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Da...	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42 intervention 2: A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum...	intervention 1: Oral iron tablets intervention 2: VIT-45	1	Norristown \| Pennsylvania \| United States \| -75.3399 \| 40.1215	352	0	0	0	NCT00396292	1COMPLETED	2006-02-01	2005-02-01	American Regent, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	45	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Wegener's granulomatosis is a primary systemic vasculitis characterized by granulomatous and necrotizing inflammation predominantly affecting the respiratory tract and the kidneys. Conventional therapy of Wegener's granulomatosis with cyclophosphamide and corticosteroids is limited by incomplete remissions and a high r...	null	Wegener's Granulomatosis	Wegener Granulomatosis Vasculitis Gusperimus Immunosuppression	null	1	arm 1: Gusperimus	[ 0 ]	1	[ 0 ]	intervention 1: SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles	intervention 1: Gusperimus	7	Prague \| N/A \| Czechia \| 14.42076 \| 50.08804 Copenhagen \| N/A \| Denmark \| 12.56553 \| 55.67594 Lübeck \| N/A \| Germany \| 10.68729 \| 53.86893 Maastricht \| N/A \| Netherlands \| 5.68889 \| 50.84833 Stockholm \| N/A \| Sweden \| 18.06871 \| 59.32938 Edinburgh \| Scotland \| United Kingdom \| -3.19648 \| 55.95206 Cambridge \| N/A \| Unit...	45	0	0	0	NCT00530075	1COMPLETED	2006-02-01	2003-12-01	Nippon Kayaku Co., Ltd.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 0 ]	144	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	false	A prospective study to evaluate the efficacy of classic homeopathic therapy compared to maintenance itraconazole therapy with and without additional exogenous lactobacillus for treatment of recurrent Candida vaginitis.	Objective: Antimycotics effectively treat sporadic and recurrent vulvovaginal candidiasis (RVVC). Classic homeopathy (CH) is also used to treat this condition. We compared the efficacy of CH and itraconazole in reducing the frequency of RVVC episodes. Design: Single-centre, prospective, randomized. Sample: One-hun...	Vulvovaginal Candidiasis	recurrent vulvovaginal candidiasis itraconazole classic homeopathy	null	3	arm 1: 6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid). arm 2: 6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid). Additionally, Lactobacillus vaginal tablets monthly given through 6 days. arm 3: CH treatment was provided by a licensed CH ...	[ 1, 1, 1 ]	3	[ 0, 0, 0 ]	intervention 1: 6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid) intervention 2: Lactobacillus vaginal tablets monthly given through 6 days intervention 3: CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised t...	intervention 1: itraconazole intervention 2: lactobacillus gasseri intervention 3: classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)	1	Vienna \| N/A \| Austria \| 16.37208 \| 48.20849	144	0	0	0	NCT00895453	1COMPLETED	2006-02-01	2000-05-01	Medical University of Vienna	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 2 ]	17	null	PARALLEL	0TREATMENT	0NONE	true	0ALL	false	Open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls. The trial consisted of a screening visit, a treatment phase and a follow-up visit. All subjects were to be treated with study medication for 8 consecutive days. Blood and urine were co...	The screening visit was performed 2 to 21 days before the first administration of study medication, the treatment phase consisted of 12 days (of which study medication was administered during the first 8 days), and the follow-up visit was performed 15 to 19 days after the first administration of study medication.	Epilepsy		null	2	arm 1: This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls arm 2: This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls	[ 5, 5 ]	1	[ 0 ]	intervention 1: None	intervention 1: BIA 2-093	1	Bloemfontein \| Bloemfontein \| South Africa \| 26.214 \| -29.12107	17	0	0	0	NCT02281526	1COMPLETED	2006-02-01	2005-05-01	Bial - Portela C S.A.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	352	RANDOMIZED	PARALLEL	0TREATMENT	null	false	0ALL	null	The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).	null	Rhinitis, Vasomotor	Vasomotor Rhinitis VMR nonallergic rhinitis GW685698X	null	1	arm 1: GW685698X	[ 0 ]	1	[ 0 ]	intervention 1: Aqueous Nasal Spray 100mcg	intervention 1: GW685698X	53	Beverly Hills \| California \| United States \| -118.40036 \| 34.07362 Huntington Beach \| California \| United States \| -117.99923 \| 33.6603 Mission Viejo \| California \| United States \| -117.672 \| 33.60002 San Diego \| California \| United States \| -117.16472 \| 32.71571 San Diego \| California \| United States \| -117.16472 \| 32...	352	0	0	0	NCT00117325	1COMPLETED	2006-02-09	2005-07-11	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	350	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).	null	Vasomotor Rhinitis Rhinitis, Vasomotor	nonallergic rhinitis GW685698X VMR vasomotor rhinitis	null	0	null	null	1	[ 0 ]	intervention 1: None	intervention 1: GW685698X	59	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Fresno \| California \| United States \| -119.77237 \| 36.74773 Irvine \| California \| United States \| -117.82311 \| 33.66946 Los Angeles \| Califo...	347	0	0	0	NCT00118703	1COMPLETED	2006-02-09	2005-07-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	506	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	The purpose of this study is to determine if Sarizotan HC1 1 mg b.i.d. (taken twice a day) is effective in the treatment of dyskinesia associated with dopaminergic treatment of Parkinson's disease (PD).	null	Parkinson's Disease Dyskinesia	Parkinson's Disease Dyskinesia Dyskinesia associated with dopaminergic treatment	null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks. intervention 2: Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks.	intervention 1: Sarizotan intervention 2: Placebo	31	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Huntsville \| Alabama \| United States \| -86.58594 \| 34.7304 La Jolla \| California \| United States \| -117.2742 \| 32.84727 Oxnard \| California \| United States \| -119.17705 \| 34.1975 Sacramento \| California \| United States \| -121.4944 \| 38.58157 Englewood \| Colora...	504	0	0	0	NCT00105508	1COMPLETED	2006-02-28	2004-09-30	EMD Serono	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	1,469	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ ...	null	Hepatitis C, Chronic		null	2	arm 1: None arm 2: None	[ 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 400mg po bid for 16 weeks intervention 2: 400mg po bid for 24 weeks intervention 3: 180 micrograms sc weekly for 16 weeks intervention 4: 180 micrograms sc weekly for 24 weeks	intervention 1: Copegus intervention 2: Copegus intervention 3: peginterferon alfa-2a [Pegasys] intervention 4: peginterferon alfa-2a [Pegasys]	132	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Anchorage \| Alaska \| United States \| -149.90028 \| 61.21806 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Little Rock \| Arkansas \| U...	1,459	3	0.002056	1	NCT00077636	1COMPLETED	2006-03-01	2003-12-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	1	0	0	0	2	0.0007
[ 4 ]	24	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This study will evaluate the benefit of adding sertraline (Zoloft®) to Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) for sexually abused children who have Posttraumatic Stress Disorder (PTSD).	Adult research has demonstrated the efficacy of selective serotonin reuptake inhibitors (SSRIs) in decreasing Posttraumatic Stress Disorder (PTSD) symptoms; to date the SSRIs are the only medication class with demonstrated efficacy in treating all three PTSD symptom clusters (reexperiencing, avoidance, and hyperarousal...	Stress Disorders, Post-Traumatic	PTSD Depression Anxiety	null	2	arm 1: Trauma-Focused CBT provided individually to youth and parent for 12 sessions (90 minute sessions; 45 minutes for youth; 45 minutes for parent); plus Sertraline provided in dosage titrated as clinically indicated by child psychiatrist blind to treatment assignment, from 50mg/day to a maximum dosage of 150 mg/day ...	[ 0, 1 ]	3	[ 5, 0, 0 ]	intervention 1: 12 weeks of Trauma-Focused CBT (TF-CBT)for youth and parent intervention 2: 12 weeks of Sertraline pill, flexible dosage of 50-150 mg/day, to be administered while receiving TF-CBT intervention 3: 12 weeks of Placebo pill, flexible dosage, of 50-150 mg/day, to be administered while receiving TF-CBT	intervention 1: Trauma-Focused Cognitive Behavioral Therapy intervention 2: Sertraline Pill intervention 3: Placebo Oral Tablet	1	Pittsburgh \| Pennsylvania \| United States \| -79.99589 \| 40.44062	22	0	0	0	NCT00078767	1COMPLETED	2006-03-01	2001-04-01	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 5 ]	57	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This study will evaluate the efficacy, safety and tolerability of PEGASYS plus ribavirin in patients with CHC who could not tolerate or were not responsive to 12 weeks of therapy with PEG-Intron plus ribavirin. The anticipated time on study treatment is 1-2 years, and the target sample size is \>100 individuals.	null	Hepatitis C, Chronic		null	2	arm 1: Participants will receive Pegasys 180 micro grams (µg or mcg) subcutaneously (SC) once a week and ribavirin 1000 or 1200 milligrams per day \[(mg/day), \< or \>=75 kilogram (Kg) body weight, respectively\], orally in divided doses for 60 weeks. arm 2: Participants will receive Pegasys 180 µg subcutaneously (SC) ...	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: 1000/1200mg po bid for 36 or 60 weeks intervention 2: 180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)	intervention 1: Ribavirin intervention 2: peginterferon alfa-2a [Pegasys]	25	Bakersfield \| California \| United States \| -119.01871 \| 35.37329 Pasadena \| California \| United States \| -118.14452 \| 34.14778 San Diego \| California \| United States \| -117.16472 \| 32.71571 San Mateo \| California \| United States \| -122.32553 \| 37.56299 Bradenton \| Florida \| United States \| -82.57482 \| 27.49893 Miami \| ...	57	0	0	0	NCT00087568	1COMPLETED	2006-03-01	2003-01-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	207	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Prolongation of the EPAAC™ trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children). 36 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in young atopic children.	null	Asthma	Pediatry EPAAC atopic Children prevention of asthma Levocetirizine Xyzal	null	3	arm 1: Levocetirizine after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ-LCTZ) arm 2: Placebo after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ - PLC) arm 3: Placebo after having been randomized to Placebo in the preceding A003...	[ 0, 2, 2 ]	2	[ 0, 10 ]	intervention 1: 5mg/mL oral drops, 0.125 mg/kg body weight, bid for 18 months intervention 2: Oral drops, bid for 18 months	intervention 1: LEVOCETIRIZINE intervention 2: Placebo	51	North Adelaide \| N/A \| Australia \| 138.59141 \| -34.90733 Parkville (North Melbourne) \| N/A \| Australia \| 144.95 \| -37.78333 Brussels \| N/A \| Belgium \| 4.34878 \| 50.85045 Brno \| N/A \| Czechia \| 16.60796 \| 49.19522 Hradec Králové \| N/A \| Czechia \| 15.83277 \| 50.20923 Olomouc \| N/A \| Czechia \| 17.25175 \| 49.59552 Ostrava ...	207	0	0	0	NCT00160563	6TERMINATED	2006-03-01	2004-06-01	UCB Pharma	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	23	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	true	1FEMALE	false	The purpose of this study is to compare post-operative pain after anesthesia with either isoflurane or propofol. Each group will be further randomized to receive intranasal nicotine or placebo in order to detect potential pronociceptive action of isoflurane. The study is a randomized, prospective, double-blinded contr...	A. Study Proposal and Rational The purpose of this study is to determine whether intranasal nicotine can decrease the negative side effects of the general anesthetic isoflurane. Isoflurane and other volatile anesthetics are potent antagonists of central nicotinic receptors. Nicotinic receptors are inhibited by isoflur...	Postoperative Pain	Postoperative pain	null	2	arm 1: Propofol anesthetic with and without nicotine arm 2: isoflurane anesthetic with and without nicotine	[ 0, 0 ]	1	[ 0 ]	intervention 1: nicotine nasal spray (3mg) before surgery	intervention 1: Nicotine (drug)	1	New York \| New York \| United States \| -74.00597 \| 40.71427	20	0	0	0	NCT00232817	1COMPLETED	2006-03-01	2003-07-01	Columbia University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3, 4 ]	70	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.	A total of 70 patients with HCC (mean age: 54.6 years, female/male: 12/58) received a liver transplant and were included in the study. Immunosuppression included de novo sirolimus, low-dose calcineurin inhibitor for 6 to 12 months, with short-course (3 months) or no steroids.	Liver Carcinoma	liver transplant hepatocellular carcinoma sirolimus	null	1	arm 1: Sirolimus given intravenously or orally to achieve serum level of 12-20ug/l	[ 0 ]	1	[ 0 ]	intervention 1: Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l	intervention 1: Sirolimus	1	Edmonton \| Alberta \| Canada \| -113.46871 \| 53.55014	70	0	0	0	NCT00328770	1COMPLETED	2006-03-01	1996-12-01	University of Alberta	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	80	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Chronic foot ulcers occurring among diabetic patients are difficult to heal. The frequent elderly age with co-morbidities, vascular insufficiencies, peripheral neuropathies and super imposed infections, all contribute towards the chronicity and failure of treatment. Preserving the ulcerated limb is the patients' wish. ...	null	Diabetic Foot Ulcer Amputation	Diabetic Foot Ulcer Traditional Chinese Medicine	null	2	arm 1: 12 herbals formulation was given as an adjuvant therapy for the patients orally twice a day. arm 2: Placebo was made with starch and colouring materials. Given to patient orally twice a day	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: The Decoction is taken orally, twice a day, treatment period is 24 weeks The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients. The formula consisted of 12 herbs, viz: Radix astragali, Rhizoma atractylodis marcocephala...	intervention 1: TCM intervention 2: Placebo	2	Hong Kong \| N/A \| China \| 114.17469 \| 22.27832 Hong Kong \| N/A \| China \| 114.17469 \| 22.27832	80	0	0	0	NCT00393510	1COMPLETED	2006-03-01	2000-11-01	Chinese University of Hong Kong	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	66	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to investigate the efficacy and safety of Cycloset® and placebo when added to metformin monotherapy (at least 1000 mg/day for 3 months prior to screening) in persons with type 2 diabetes mellitus who are not adequately controlled on metformin therapy alone.	In the previously conducted Phase III clinical trials, Cycloset® (up to a maximum dose of 4.8 mg/day), administered either as monotherapy or combined with sulfonylurea therapy, significantly reduced HbA1c, fasting and post-prandial glucose and fasting and post-prandial triglycerides in obese individuals with type 2 dia...	Type 2 Diabetes	diabetes diabetes mellitus	null	2	arm 1: Bromocriptine mesylate 0.8 mg arm 2: Bromocriptine mesylate 0.8 mg matching placebo	[ 1, 2 ]	1	[ 0 ]	intervention 1: 0.8 mg tablet	intervention 1: Bromocriptine Mesylate	0	null	66	0	0	0	NCT00441363	6TERMINATED	2006-03-01	2005-02-01	VeroScience	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	16	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	true	0ALL	false	This was a phase 1, double-blind, 4-way crossover study in healthy male and female volunteers. Subjects received 4 formulations of intranasal ketorolac tromethamine 30 mg. There was a wash-out period of 3-7 days between each dose. On Day 1 of each period subjects were randomised to receive either a single intranasal do...	null	Healthy Volunteers		null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 30 mg Ketorolac Tromethamine intranasal (IN) intervention 2: 30 mg Ketorolac Tromethamine with 4% Lidocaine HCl IN intervention 3: 30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN intervention 4: 30 mg Ketorolac Tromethamine with 6% Lidocaine HCl IN	intervention 1: Ketorolac Tromethamine intervention 2: Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl) intervention 3: Ketorolac Tromethamine with 5% Lidocaine HCl intervention 4: 30 mg Ketorolac Tromethamine with 6% Lidocaine HCl	1	Manchester \| N/A \| United Kingdom \| -2.23743 \| 53.48095	64	0	0	0	NCT01355588	1COMPLETED	2006-03-01	2005-08-01	Egalet Ltd	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	215	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	null	This was a prospective, open-label, non-comparative, Phase IIIb trial to assess the convenience, safety and efficacy of the new Gonal-F fbm \[recombinant follicle stimulating hormone (r-FSH)\] liquid formulation, in common setting for ovulation induction (OI) and also in in-vitro fertilization (IVF).	null	Infertility Ovulation Induction In-Vitro Fertilization	Infertility Ovulation induction Gonal-F Follitropin alpha Controlled ovarian stimulation	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro...	intervention 1: GONAL-f®	1	Darmstadt \| N/A \| Germany \| 8.65027 \| 49.87167	215	0	0	0	NCT01183143	1COMPLETED	2006-03-02	2004-05-11	Merck KGaA, Darmstadt, Germany	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	198	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study was to demonstrate in adult participants faster recovery from a neuromuscular block induced by either rocuronium or vecuronium after reversal at reappearance of T2 (the amplitude of the first response of second twitch to train of four (TOF) stimulation, expressed as percentage of control first...	null	Anesthesia, General		null	4	arm 1: After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered arm 2: After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered arm 3: After the last dose of vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammade...	[ 0, 1, 0, 1 ]	2	[ 0, 0 ]	intervention 1: After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was to be administered intervention 2: After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered	intervention 1: Sugammadex intervention 2: Neostigmine	0	null	189	0	0	0	NCT00451217	1COMPLETED	2006-03-06	2005-11-17	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	514	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The Early Prevention of Asthma in Atopic Children (EPAAC™). 24 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24 months old children.	null	Dermatitis, Atopic	EPAAC Atopic children Asthma XYZAL Levocetirizine	null	2	arm 1: 0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily. arm 2: Placebo was administered as oral drops twice daily.	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Pharmaceutical form: Oral drops Route of administration: Oral use intervention 2: Pharmaceutical form: Oral drops Concentration: 5 mg/ml Route of administration: Oral use	intervention 1: Placebo intervention 2: Levocetirizine	0	null	510	0	0	0	NCT00152464	1COMPLETED	2006-03-15	2002-03-20	UCB Pharma SA	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	385	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	This study will examine the viral kinetics and pharmacokinetics of Pegasys plus ribavirin and PEG-Intron plus ribavirin in interferon-naive patients with CHC. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.	null	Hepatitis C, Chronic		null	2	arm 1: Participants received Peginterferon alfa-2a (40 kD) \[Pegasys\] at a dosage of 180 microgram (μg), subcutaneously (SC), once a week plus Ribavirin \[Copegus\] 1000 or 1200 milligram (mg)/day), orally, \[according to body weight, lesser than or greater than/equal to (\< or \>/=) 75 kilogram (kg), respectively\] t...	[ 0, 1 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 1000/1200mg/day po intervention 2: 1.5 micrograms/kg sc weekly intervention 3: 1000/1200mg/day po intervention 4: 180 micrograms sc weekly	intervention 1: Ribavirin intervention 2: Peginterferon alfa-2b (PEG-Intron) intervention 3: Ribavirin intervention 4: Peginterferon alfa-2a [Pegasys]	41	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Sacramento \| California \| United States \| -121.4944 \| 38.58157 San Diego \| California \| United States \| -117.16472 \| 32.71571 San Diego \| California \| United States \| -117.16472 \| 32.71571 San Franc...	377	0	0	0	NCT00087607	1COMPLETED	2006-04-01	2004-01-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	58	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	false	Identifying new approaches for preventing breastmilk transmission of HIV-1 is an important research priority. To this end, clinical trials are underway to evaluate the efficacy of HAART (zidovudine, lamivudine, nevirapine) during late pregnancy/lactation versus zidovudine/nevirapine peripartum for prevention of breastm...	This will be a randomized study comparing breastfeeding women receiving zidovudine/nevirapine (from 36 weeks to delivery/first day postpartum) to women receiving HAART (zidovudine, nevirapine, lamivudine) initiated at 36 weeks and continuing throughout lactation (recommended for 6 months, breastfeeding cessation prior ...	HIV Infections	breastmilk HIV-1 antiretroviral mother-to-child transmission	null	2	arm 1: Combined short-course Zidovudine/Nevirapine arm 2: HAART during pregnancy and 6 months postpartum	[ 1, 0 ]	2	[ 0, 0 ]	intervention 1: 300 mg of ZDV was given twice daily from 34 weeks gestation until labor then every 3 hours until delivery; 200 mg of NVP was given as a single oral dose at the onset of labor; and a single 2 mg/kg (6 mg if birthweight \> 2.5 kg) oral dose of NVP suspension was administered to the infant within 72 hours ...	intervention 1: Combined short-course zidovudine/nevirapine intervention 2: HAART	1	Nairobi \| N/A \| Kenya \| 36.81667 \| -1.28333	50	0	0	0	NCT00167674	1COMPLETED	2006-04-01	2003-11-03	University of Washington	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	41	RANDOMIZED	PARALLEL	2DIAGNOSTIC	4QUADRUPLE	false	0ALL	true	The aim of the study is to investigate the efficacy and safety of EGb 761® in patients with the primary Raynaud phenomenon, with regards to the frequency, duration and severity of vasospastic attacks.	Despite more than 150 years of research into the pathophysiology of Raynaud´s phenomenon it is still not understood sufficiently. Three mean mechanisms responsible for Raynaud´s phenomenon are discussed and fall into the following three categories: * neurological malfunction * pathological blood vessel wall and blood ...	Raynaud Disease	Raynaud´s phenomenon Vasospastic attacks Ginkgo biloba	null	2	arm 1: Receiving daily Ginkgo biloba extract EGb 761 arm 2: Receiving daily placebo	[ 0, 2 ]	1	[ 0 ]	intervention 1: daily Ginkgo biloba extract EGb 761	intervention 1: Ginkgo biloba extract EGb 761	1	Nijmegen \| Gelderland \| Netherlands \| 5.85278 \| 51.8425	41	0	0	0	NCT00251238	1COMPLETED	2006-04-01	2005-11-01	VSM Geneesmiddelen b.v.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	551	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of the study is to assess the efficacy comparability of cetirizine and levocetirizine, by comparing the effects of single intake of the two drugs to placebo in reducing symptoms of seasonal allergic rhinitis (SAR) in ragweed sensitive adult subjects exposed to ragweed pollen in an Environmental Exposure Uni...	null	Rhinitis Allergic Seasonal	Levocetirizine Xyzal Rhinitis Allergic Seasonal Ragweed	null	5	arm 1: A single dose of placebo was administered orally on Day 1. arm 2: A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1. arm 3: A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1. arm 4: A single dose of 5 mg of CTZ oral drops was administered orally on Day 1. arm 5:...	[ 2, 0, 0, 0, 0 ]	7	[ 0, 0, 0, 0, 0, 0, 0 ]	intervention 1: * Pharmaceutical form: Drops for oral administration * Route of administration: Oral use intervention 2: * Pharmaceutical form: Tablets for oral administration * Route of administration: Oral use intervention 3: * Pharmaceutical form: Tablets for oral administration * Route of administration: Oral use i...	intervention 1: Placebo drops intervention 2: Placebo tablets matching to levocetirizine intervention 3: Placebo tablets matching to cetirizine intervention 4: Levocetirizine drops intervention 5: Levocetirizine tablets intervention 6: Cetirizine drops intervention 7: Cetirizine tablets	1	Kingston \| Ontario \| Canada \| -76.48098 \| 44.22976	551	0	0	0	NCT00291642	1COMPLETED	2006-04-01	2006-01-01	UCB Pharma	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 0 ]	2	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	Greater Occipital Nerve Blocks (GONB) are a common procedure used for the treatment of headache. The GONB procedure involves a series of injections into the greater occipital nerve (a spinal nerve located at the back of your head). The purpose of this study is to determine whether GONB is effective for the treatment of...	null	Migraine		null	2	arm 1: None arm 2: matching volume of saline injected	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headach...	intervention 1: 0.5% bupivicaine and 2% lidocaine intervention 2: Saline placebo	1	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	2	0	0	0	NCT00329732	6TERMINATED	2006-04-01	2006-03-01	Thomas Jefferson University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	126	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Allergic rhinitis(AR) is one of the most common allergic disorders throughout the world.The conventional therapies are effective in alleviating symptoms but the efficacy are limited and not persistent. Furthermonre, the cost and side-effect are known defects. A classical Chinese herbal formula, has been used for AR for...	It is a randomized, double-blind, placebo-controlled trial.	Perennial Allergic Rhinitis	Perennial Allergic rhinitis Traditional Chinese Medicine	null	2	arm 1: Consist of 6 herbal. 7.5 g Xanthium sibiricum Patrin ex Widder (Asteraceae, Fructus), 20 g Angelica dahurica (Fisch. ex Hoffm.) Benth. (Apiaceae, Radix), 7.5 g Saposhnikovia divaricata (Turcz.) Schischk. (Apiaceae, Radix),15 g Magnolia biondii Pamp., (Magnoliaceae, Flos), 5 g Gentiana scabra Bunge (Gentianaceae,...	[ 1, 2 ]	2	[ 0, 10 ]	intervention 1: 4 weeks of treatment, dose of 1 g (two capsules), twice daily intervention 2: 4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily	intervention 1: Shi-Bi-Lin intervention 2: Placebo	2	Hong Kong \| N/A \| Hong Kong \| 114.17469 \| 22.27832 Hong Kong \| N/A \| Hong Kong \| 114.17469 \| 22.27832	126	0	0	0	NCT00456755	1COMPLETED	2006-04-01	2004-03-01	Chinese University of Hong Kong	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 2 ]	36	RANDOMIZED	CROSSOVER	null	0NONE	true	0ALL	null	The objective of this study is to compare the rate and extent of absorption of two Tramadol Contramid® OAD 300 mg controlled-release tablets from two different manufacturing sites, administered as 1 x 300 mg controlled-release tablet under fasting conditions. The effect of food on the to-be-marketed formulation was als...	null	Healthy	Healthy Subjects	null	3	arm 1: None arm 2: None arm 3: None	[ 0, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: 1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall. intervention 2: 1x300mg Tramadol Hydrochloride (HCl...	intervention 1: Tramadol hydrochloride intervention 2: Tramadol HCl intervention 3: Tramadol HCl	0	null	108	0	0	0	NCT00834912	1COMPLETED	2006-04-01	2006-02-01	Labopharm Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	43	RANDOMIZED	CROSSOVER	0TREATMENT	1SINGLE	false	0ALL	false	The objective of this study is to investigate the pharmacodynamics (as expressed in intraocular pressure \[IOP\]) of two formulations of tafluprost 0.0015% eyedrops (preserved and unpreserved) in patients with open-angle glaucoma or ocular hypertension. The primary aim of this study is to show that IOP reduction betwe...	null	Open-Angle Glaucoma Ocular Hypertension	Ocular hypertension	null	2	arm 1: None arm 2: None	[ 0, 0 ]	1	[ 0 ]	intervention 1: Eye drops, 0.015 mg/ml, once daily to affected eye(s)	intervention 1: Tafluprost 0.0015%	3	Oulu \| N/A \| Finland \| 25.46816 \| 65.01236 Regensburg \| N/A \| Germany \| 12.10161 \| 49.01513 Starnberg \| N/A \| Germany \| 11.34416 \| 48.00193	85	0	0	0	NCT00918346	1COMPLETED	2006-04-01	2005-09-01	Santen Oy	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	477	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	The primary trial objective is to determine the clinically effective dose of orally administered pyronaridine/artesunate (Pyramax®, PA) with a 3:1 ratio to treat adults with acute, symptomatic, uncomplicated P. falciparum malaria in South East Asia and Africa. Secondary trial objectives are to determine the safety of o...	This is a double-blind, multicentre, randomized, parallel group, dose-finding study of the efficacy, safety and tolerability of a once-daily 3-day regimen of PA with a 3:1 weight/weight ratio for patients with acute, symptomatic, uncomplicated P. falciparum malaria. Patients will be recruited from 5 to 7 study sites in...	Plasmodium Falciparum Malaria	malaria antimalarial artemisinin based combination therapy (ACT) pyronaridine artesunate (Pyramax)	null	3	arm 1: pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg arm 2: pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg arm 3: pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg	[ 0, 0, 0 ]	1	[ 0 ]	intervention 1: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1. The tablets were taken daily for 3 days.	intervention 1: pyronaridine/artesunate	6	Pailin \| N/A \| Cambodia \| 102.60928 \| 12.84895 Tomohon \| North Sulawesi \| Indonesia \| 124.80379 \| 1.31678 Guédiawaye \| N/A \| Senegal \| -17.40212 \| 14.77446 Bangkok \| N/A \| Thailand \| 100.50144 \| 13.75398 Farafenni \| N/A \| The Gambia \| -15.6 \| 13.56667 Mbarara \| N/A \| Uganda \| 30.64851 \| -0.60467	476	0	0	0	NCT01594931	1COMPLETED	2006-04-01	2005-07-01	Medicines for Malaria Venture	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	35	null	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to characterize the pharmacokinetics of Eslicarbazepine acetate in children and adolescents with epilepsy.	This clinical study was planned to be performed as an open-label, single-centre, multiple-dose study, in 30 paediatric epileptic patients distributed by 3 age groups of 10 patients each: 2-6 years \[Group 1\], 7-11 years \[Group 2\], and 12-17 years \[Group 3\]. The study was constituted by a 4-week baseline phase, fo...	Epilepsy	Epilepsy BIA 2-093	null	3	arm 1: At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1...	[ 0, 0, 0 ]	1	[ 0 ]	intervention 1: Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route	intervention 1: BIA 2-093 (Eslicarbazepine acetate)	1	Bucharest \| N/A \| Romania \| 26.10626 \| 44.43225	31	0	0	0	NCT02170064	1COMPLETED	2006-04-01	2005-06-01	Bial - Portela C S.A.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	19	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	This study will evaluate the safety, tolerability, and pharmacokinetics of the combination of rhuMab 2C4 (Perjeta) and docetaxel (Taxotere) in participants with advanced solid tumors that have progressed during or after standard therapy, or for which no standard therapy is available. Participants will be enrolled and e...	null	Solid Tumor		null	3	arm 1: Docetaxel will be administered via intravenous (IV) infusion on Day 1 of each 3-week cycle at a dose of 100 mg/m\^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg l...	[ 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m\^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal. intervention 2: Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV...	intervention 1: Docetaxel intervention 2: RhuMab 2C4	2	Rotterdam \| N/A \| Netherlands \| 4.47917 \| 51.9225 Sutton \| N/A \| United Kingdom \| -0.2 \| 51.35	19	0	0	0	NCT02490475	1COMPLETED	2006-04-01	2004-02-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2, 3 ]	78	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The primary purpose of this study is to assess the safety and efficacy of interferon-gamma by subcutaneous injection in complex treatment of patients with co-infection of HIV and pulmonary tuberculosis and to determine the rational of its use.	Study will evaluate safety and efficacy of the investigational medical product (IMP) - interferon-gamma - in participants with HIV-infection and pulmonary tuberculosis. Interferon-gamma (immune interferon) is an important anti-inflammatory cytokine produced by NK-cells, CD4 Th1 cells and CD8 cytotoxic supressor cells....	HIV Coinfection Aids/Hiv Problem Tuberculosis, Pulmonary Human Immunodeficiency Virus Lentivirus Infections RNA Virus Infections	interferon gamma, IFN-g, HIV infection, tuberculosis	null	3	arm 1: All participants receive subcutaneous interferon-gamma (Ingaron®) 500,000 IU alternated with Interal® (interferon alpha) 3,000,000 IU every other day Interventions: Drug: Ingaron® Drug: Interal® Drug: Antituberculosis complex therapy arm 2: All participants receive subcutaneous interferon-gamma (Ingaron®) 500,...	[ 0, 0, 4 ]	1	[ 0 ]	intervention 1: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein	intervention 1: Interferon-Gamma	2	Saint Petersburg \| Sankt-Peterburg \| Russia \| 30.31413 \| 59.93863 Saint Petersburg \| Sankt-Peterburg \| Russia \| 30.31413 \| 59.93863	78	0	0	0	NCT05065905	1COMPLETED	2006-04-06	2006-01-19	SPP Pharmaclon Ltd.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	248	RANDOMIZED	PARALLEL	0TREATMENT	null	false	0ALL	false	During this study, your child will need to attend up to 5 office visits and maintain regular telephone contact with the clinic. Certain office visits will include physical exams, medical history review, exercise challenge test (walking/running on a treadmill), electrocardiogram (ECG) tests, and lung function tests. All...	null	Bronchospasm Activity/Exercise Induced Bronchospasm	asthma bronchospasm	null	2	arm 1: Participants received FSC 100/50 microgram (mcg) one inhalation as a combination product via DISKUS, twice daily in morning after awakening and in evening for up to 28 days arm 2: Participants received FP 100 mcg one inhalation via DISKUS, twice daily in morning after awakening and in evening for up to 28 days.	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Fluticasone propionate/salmeterol intervention 2: Fluticasone Propionate	intervention 1: Fluticasone propionate/salmeterol intervention 2: Fluticasone Propionate	50	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Huntington Beach \| California \| United States \| -117.99923 \| 33.6603 Orange \| California \| United States \| -117.85311 \| 33.78779 Palmdale \| California \| United States \| -118.11646 \| 34.57943 Paramount \| California \| United States \| -118.15979 \| 33.88946 San ...	248	0	0	0	NCT00118716	1COMPLETED	2006-04-23	2003-12-23	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	9	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This was a Phase 1, single-arm, open-label, pilot study of NY-ESO-1 protein vaccination with imiquimod as an adjuvant in patients with resected Stage IIB, IIC, and III malignant melanoma. The primary study objective was to determine the safety of NY-ESO-1 protein/imiquimod treatment, and the secondary objective was to ...	Patients applied imiquimod (250 mg) topically to a designated area of healthy skin on the upper inner arm or inner thigh (the cream remained on the skin overnight for 6-10 hours) every day for 5 consecutive days (i.e., for the first 5 days of Cycles 1-3 and for the first 4 days of Cycle 4). The NY-ESO-1 protein (100 μg...	Malignant Melanoma	Malignant melanoma Stages IIB-III	null	1	arm 1: Patients applied topical imiquimod followed by vaccination with intradermal injections of the NY-ESO-1 protein.	[ 0 ]	2	[ 0, 2 ]	intervention 1: Patients applied imiquimod cream at bedtime every day for 5 consecutive days (for the first 5 days of Cycles 1-3 and for the first 4 days of Cycle 4) at a dose of 250 mg as supplied in single-use packets to a 4 x 5 cm area of healthy skin, alternating among the extremities (upper inner arms and inner th...	intervention 1: Imiquimod intervention 2: NY-ESO-1 protein	1	New York \| New York \| United States \| -74.00597 \| 40.71427	9	0	0	0	NCT00142454	1COMPLETED	2006-04-25	2005-08-24	Ludwig Institute for Cancer Research	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	521	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus.	null	Diabetes Mellitus, Type 2		null	3	arm 1: Sitagliptin 100 mg arm 2: Sitagliptin 200 mg arm 3: Placebo/Pioglitazone	[ 0, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: sitagliptin 100 mg oral tablet once daily for 54 weeks intervention 2: sitagliptin 200 mg (2- 100 mg oral tablets) once daily for 54 weeks intervention 3: placebo oral tablet once daily during Phase A (Weeks 0-18) intervention 4: pioglitazone 30 mg oral tablet once daily during Phase B (Weeks 18-54)	intervention 1: Comparator: sitagliptin 100 mg intervention 2: Comparator: sitagliptin 200 mg intervention 3: Comparator: placebo intervention 4: Comparator: pioglitazone	0	null	521	0	0	0	NCT00094757	1COMPLETED	2006-04-28	2004-10-06	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	104	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Objective(s) The primary study objective is to assess the antiviral effect of 12 weeks of adefovir dipivoxil treatment in Korean patients with chronic hepatitis B and compensated liver disease. The secondary study objectives are to assess the antiviral effect, clinical benefit and safety of 52 weeks of adefovir dipivox...	null	Hepatitis B, Chronic		null	1	arm 1: All enrolled subject were enrolled to adefovir dipivoxil 10mg arm.	[ 0 ]	1	[ 0 ]	intervention 1: All enrolled subjects were enrolled to adefovir dipivoxil arm.	intervention 1: Adefor dipivoxil	0	null	104	0	0	0	NCT01205165	1COMPLETED	2006-04-28	2004-12-17	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	2,101	RANDOMIZED	PARALLEL	1PREVENTION	2DOUBLE	false	0ALL	null	A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the ef ficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule s \[150 or 220 mg once daily starting with a half dose (i.e.75 or 110 mg) on the day of surgery\] comp ared to subcuta...	null	Arthroplasty, Replacement, Knee Thromboembolism		null	3	arm 1: 220 mg once daily arm 2: 150 mg once daily arm 3: 40 mg once daily	[ 0, 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: 40 mg once daily intervention 2: 150 mg once daily intervention 3: 220 mg once daily	intervention 1: enoxaparin intervention 2: dabigatran etexilate intervention 3: dabigatran etexilate	105	Garren \| Australian Capital Territory \| Australia \| N/A \| N/A Kogarah \| New South Wales \| Australia \| 151.13564 \| -33.9681 Lismore \| New South Wales \| Australia \| 153.2773 \| -28.81354 Bedford Park \| South Australia \| Australia \| 138.56815 \| -35.02204 Toorak Gardens \| South Australia \| Australia \| 138.63639 \| -34.93478 ...	2,076	1	0.000482	0	NCT00168805	1COMPLETED	2006-05-01	2004-11-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0	1	0	0	0	0.000085
[ 5 ]	308	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	null	This study will evaluate whether an early positive response to once-monthly oral ibandronate in treatment-naive participants with postmenopausal osteoporosis is predictive of efficacy later in treatment. The anticipated time on study treatment is 6 months, and the target sample size is 360 individuals.	null	Post Menopausal Osteoporosis		null	2	arm 1: Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 1 will receive a physician consultation after 4 months of treatment to review bone turnover test results. arm 2: Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 2 will not r...	[ 0, 0 ]	1	[ 0 ]	intervention 1: Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.	intervention 1: Ibandronate	53	Montgomery \| Alabama \| United States \| -86.29997 \| 32.36681 Chandler \| Arizona \| United States \| -111.84125 \| 33.30616 Peoria \| Arizona \| United States \| -112.23738 \| 33.5806 Hot Springs \| Arkansas \| United States \| -93.05518 \| 34.5037 Pine Bluff \| Arkansas \| United States \| -92.0032 \| 34.22843 Anaheim \| California \| U...	308	1	0.003247	1	NCT02598934	1COMPLETED	2006-05-01	2004-08-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	1	0	0	0	0	0.000573
[ 3 ]	35	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II ...	OBJECTIVES: Primary * Determine the effects of hepatic enzyme-inducing drugs, such as anticonvulsants, on the pharmacokinetics of celecoxib in patients with newly diagnosed glioblastoma multiforme undergoing radiotherapy. * Determine the effects of steroids on the pharmacokinetics of celecoxib in these patients. Sec...	Brain and Central Nervous System Tumors	adult glioblastoma adult giant cell glioblastoma adult gliosarcoma	null	2	arm 1: on p450 inhibitor (Patients taking anttiseizure drugs that are known to induce the hepatic drug-metabolizing enzymes - including phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine) celecoxib and radiation therapy will be adminstered with this arm arm 2: not on p450 inhibitor (Patients either N...	[ 1, 1 ]	2	[ 4, 0 ]	intervention 1: Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment intervention 2: Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2...	intervention 1: radiation therapy intervention 2: Celecoxib	7	Tampa \| Florida \| United States \| -82.45843 \| 27.94752 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038 Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Winston-Salem \| North Carolina \| United States \| -80.24422 \| 36.09986 Cleveland \| Ohio \|...	35	0	0	0	NCT00068770	6TERMINATED	2006-05-01	2003-10-01	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	462	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	2MALE	false	A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.	This will be a multi-center, double-blind, placebo controlled, parallel, 12 week treatment trial in men with signs and symptoms of benign prostatic hyperplasia. the following procedures are utilized: physical exams, electrocardiograms, clinical laboratory tests, vital signs, the Internation Prostate Symptom Score, maxi...	Benign Prostatic Hyperplasia	Benign prostatic hyperplasia, alpha blocker	null	2	arm 1: Silodosin 8 mg/Day with food arm 2: Matching placebo capsule once daily with food	[ 0, 2 ]	2	[ 0, 10 ]	intervention 1: 8 mg daily for 12 weeks intervention 2: One capsule daily for 12 weeks	intervention 1: Silodosin intervention 2: Placebo	42	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Carmichael \| California \| United States \| -121.32828 \| 38.61713 Fresno \| California \| United States \| -119.77237 \| 36.74773 Laguna Woods \| California \| United States \| -117.72533 \| 33.6103 San Bernardino \| California \| United States \| -117.28977 \| 34.10834 Tar...	462	0	0	0	NCT00224120	1COMPLETED	2006-05-01	2005-05-01	Watson Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	420	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The purpose of this study is to investigate the efficacy and safety of an MK 0974 for migraine headache and to identify an appropriate dose range for further study.	null	Migraine		null	9	arm 1: Placebo to match assigned treatment arm; one orally-administered dose, plus an optional second dose of active drug, per assigned treatment arm, to treat a single moderate-to-severe migraine headache. arm 2: MK0974 25 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moder...	[ 2, 0, 0, 0, 0, 0, 0, 0, 1 ]	9	[ 0, 0, 0, 0, 0, 0, 0, 0, 0 ]	intervention 1: Placebo to match assigned treatment arm; one orally-administered dose intervention 2: MK0974 25 mg; one orally-administered dose intervention 3: MK0974 50 mg; one orally-administered dose intervention 4: MK0974 100 mg; one orally-administered dose intervention 5: MK0974 200 mg; one orally-administered d...	intervention 1: Comparator: Placebo intervention 2: MK0974 intervention 3: MK0974 intervention 4: MK0974 intervention 5: MK0974 intervention 6: MK0974 intervention 7: MK0974 intervention 8: MK0974 intervention 9: Rizatriptan	0	null	330	0	0	0	NCT00246337	1COMPLETED	2006-05-01	2005-11-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	-0
[ 5 ]	36	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	This is a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single center study in subjects with positive histamine skin prick test and a positive RadioAllergoSorbent Test (RAST) (class \> 2) to one of the tested standardized allergenic extracts: tree pollen, cat dander, house dust mite, or a ...	null	Hypersensitivity	Histamine H1 Antagonists Anti-Allergic Agents	null	3	arm 1: Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4). arm 2: Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4). arm 3: Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (v...	[ 0, 1, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 5 mg tablet once daily intervention 2: 5 mg capsule once daily intervention 3: once daily intervention 4: once daily	intervention 1: desloratadine intervention 2: levocetirizine intervention 3: Desloratadine placebo tablet intervention 4: Levocetirizine placebo capsule	0	null	36	0	0	0	NCT00359138	1COMPLETED	2006-05-01	2006-02-01	Organon and Co	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	466	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Korean double-blind non-inferiority study to asses the efficacy (as measured by the responder rate of pruritus severity score by the patient at visit 4 or end-of-treatment visit over the 2 weeks treatment period) and safety of Xyzal® to Zyrtec® in subjects suffering from dermatitis and eczema with pruritus symptoms	null	Dermatitis Eczema	Dermatitis Eczema Pruritus Xyzal Zyrtec Levocetirizine Cetirizine	null	2	arm 1: Levocetirizine + Cetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for 14 days arm 2: Cetirizine + Levocetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for 14 days	[ 0, 1 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: 1 Levocetirizine 5mg tablet per day before bedtime for 14 days intervention 2: 1 Cetirizine 10mg tablet per day before bedtime for 14 days. intervention 3: 1 Placebo-Levocetirizine tablet per day before bedtime for 14 days intervention 4: 1 Placebo-Cetirizine tablet per day before bedtime for 14 days in...	intervention 1: Levocetirizine intervention 2: Cetirizine intervention 3: Placebo-Levocetirizine intervention 4: Placebo-Cetirizine intervention 5: Standard topical steroid (1% hydrocortisone) ointment	3	Gyeunggi-do \| N/A \| South Korea \| N/A \| N/A Kyeonggi-Do \| N/A \| South Korea \| N/A \| N/A Seoul \| N/A \| South Korea \| 126.9784 \| 37.566	423	0	0	0	NCT00375713	1COMPLETED	2006-05-01	2005-10-01	UCB Pharma	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	16	RANDOMIZED	CROSSOVER	0TREATMENT	3TRIPLE	true	0ALL	false	The purpose of this study is to evaluate the tolerability and pharmacokinetics of three doses of MAP0010 (Unit Dose Budesonide) compared with Pulmicort Respules® (Budesonide) in healthy volunteers.	null	Asthma	Pediatric asthma	null	4	arm 1: Treatment visits were separated by a 48-72 hour washout period. Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 2; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 3; Treatment D = a single dose of MAP0010 ...	[ 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol. intervention 2: Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol....	intervention 1: Budesonide Inhalation Suspension intervention 2: MAP0010 low dose intervention 3: MAP0010 intermediate dose intervention 4: MAP0010 high dose	1	Brisbane \| Queensland \| Australia \| 153.02809 \| -27.46794	64	0	0	0	NCT00627679	1COMPLETED	2006-05-01	2005-12-01	Allergan	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	292	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	This 4 arm study will evaluate the efficacy and safety of RO4607381 when co-administered with pravastatin in patients with low or relatively low HDL-C levels. Patients will be randomised to one of 4 groups to receive either RO4607381 300mg, 600mg or 900mg po daily, or placebo po daily, for 12 weeks.All patients will al...	null	Dyslipidemia		null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 0, 0, 0, 2 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: po daily for 12 weeks intervention 2: 40mg po daily for 12 weeks intervention 3: 300mg po daily for 12 weeks intervention 4: 600mg po daily for 12 weeks intervention 5: 900mg po daily for 12 weeks	intervention 1: Placebo intervention 2: Pravastatin intervention 3: Dalcetrapib intervention 4: Dalcetrapib intervention 5: Dalcetrapib	33	Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Newark \| Delaware \| United States \| -75.74966 \| 39.68372 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Evansville \| Indiana \| United Sta...	292	0	0	0	NCT00697203	1COMPLETED	2006-05-01	2005-07-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	594	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	0ALL	false	The objective of this study is to evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia	Evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia	Anemia		null	2	arm 1: Day 0: 15 mg/kg up to a maximum dose of 1,000 mg of iron as VIT-45 over 15 minutes intravenously. Day 7: for weight \>33 kg, 250 cc of normal saline and for weight ≤33 kg, 100 cc of normal saline over 15 minutes intravenously. arm 2: Day 0: for weight \>33 kg, 250 cc of normal saline and for weight ≤33 kg, 100 ...	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: 15 mg/kg up to a maximum dose of 1,000 mg of iron as VIT-45 over 15 minutes intravenously intervention 2: for weight \>33 kg, 250 cc of normal saline and for weight ≤33 kg, 100 cc of normal saline over 15 minutes intravenously	intervention 1: VIT-45 intervention 2: Placebo	1	Norristown \| Pennsylvania \| United States \| -75.3399 \| 40.1215	1,153	0	0	0	NCT00740246	1COMPLETED	2006-05-01	2005-07-01	American Regent, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	26	RANDOMIZED	CROSSOVER	null	1SINGLE	true	0ALL	false	This study investigated the relative bioavailability (rate and extent of absorption) of Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg by Teva Pharmaceuticals, USA with that of Aricept® Orally Disintegrating Tablets, Manufactured and Marketed by Eisai Inc., following a single oral dose (1 x 10 mg orally d...	null	Healthy	Bioequivalence Healthy Subjects	null	2	arm 1: Donepezil Hydrochloride 10 mg Orally Disintegrating Tablets arm 2: Aricept® 10 mg Orally Disintegrating Tablets	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 10 mg Orally Disintegrating Tablet intervention 2: 10 mg Orally Disintegrating Tablet	intervention 1: Donepezil Hydrochloride intervention 2: Aricept®	1	East Grand Forks \| Minnesota \| United States \| -97.02452 \| 47.92998	52	0	0	0	NCT01260922	1COMPLETED	2006-05-01	2006-04-01	Teva Pharmaceuticals USA	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	26	RANDOMIZED	CROSSOVER	null	0NONE	true	0ALL	false	This study investigated the relative bioavailability (rate and extend of absorption) of Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg by Teva Pharmaceuticals, USA with that of Aricept® Orally Disintegrating Tablets, Manufactured and Marketed by Eisai Inc., following a single oral dose (1 x 10 mg orally d...	null	Healthy	Bioequivalence Healthy Subjects	null	2	arm 1: Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg arm 2: Aricept® Orally Disintegrating Tablets, 10 mg	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 10 mg Orally Disintegrating Tablet intervention 2: 10 mg Orally Disintegrating Tablet	intervention 1: Donepezil Hydrochloride intervention 2: Aricept®	1	East Grand Forks \| Minnesota \| United States \| -97.02452 \| 47.92998	52	0	0	0	NCT01260948	1COMPLETED	2006-05-01	2006-04-01	Teva Pharmaceuticals USA	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	232	RANDOMIZED	PARALLEL	2DIAGNOSTIC	3TRIPLE	false	0ALL	false	The object of this study is to compare four different dosages of Gadavist 1.0 in cardiac Magnetic Resonance Tomography (MRT) imaging with the imaging results of a cardiac SPECT examination in terms of diagnostic quality. For this purpose Gadavist dosages of 0.01 mmol/kg, 0.025 mmol/kg, 0.05 mmol/kg or 0.1mmol/kg body ...	null	Myocardial Perfusion Imaging Magnetic Resonance Imaging	Cardiac MRI gadobutrol	null	4	arm 1: Participants received 1 i.v. bolus injections of Gadobutrol 0.01 mmol/kg body weight (BW) (0.01mL/kg) for stress magnetic resonance imaging (MRI) via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.01 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor...	[ 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 0.01 mmol/kg BW (0.01 mL/kg) for stress MRI and 0.01 mmol/kg BW (0.01 mL/kg) for rest MRI (total dose 0.02 mmol/kg) intervention 2: 0.025 mmol/kg BW (0.025 mL/kg) for stress MRI and 0.025 mmol/kg BW (0.025 mL/kg) for rest MRI (total dose 0.05 mmol/kg) intervention 3: 0.05 mmol/kg BW (0.05 mL/kg) for str...	intervention 1: Gadobutrol (Gadavist,Gadovist, BAY86-4875) intervention 2: Gadobutrol (Gadavist,Gadovist, BAY86-4875) intervention 3: Gadobutrol (Gadavist,Gadovist, BAY86-4875) intervention 4: Gadobutrol (Gadavist,Gadovist, BAY86-4875)	14	Pölten \| N/A \| Austria \| 15.96667 \| 46.73333 Freiburg im Breisgau \| Baden-Wurttemberg \| Germany \| 7.85222 \| 47.9959 Tübingen \| Baden-Wurttemberg \| Germany \| 9.05222 \| 48.52266 Ulm \| Baden-Wurttemberg \| Germany \| 9.99155 \| 48.39841 München \| Bavaria \| Germany \| 13.46314 \| 48.69668 München \| Bavaria \| Germany \| 13.46314 ...	226	0	0	0	NCT01490294	1COMPLETED	2006-05-01	2004-03-01	Bayer	4INDUSTRY	false	false	false	null	0	0	0	0	0	-0
[ 3 ]	64	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The primary objective of this trial is to establish the maximum maintenance dose of SPM 962 in patients with Parkinson's disease in a multi-center, uncontrolled, open-label study by conducting safety evaluation of each patient following once-daily transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg. (The admi...	null	Parkinson's Disease	SPM 962 rotigotine Parkinson's disease	null	1	arm 1: SPM 962 transdermal patch	[ 0 ]	1	[ 0 ]	intervention 1: SPM 962 transdermal patch once a daily up to 36.0 mg/day	intervention 1: SPM 962	5	Kanto Region \| N/A \| Japan \| N/A \| N/A Kinki Region \| N/A \| Japan \| N/A \| N/A Kyushu Region \| N/A \| Japan \| N/A \| N/A Shikoku Region \| N/A \| Japan \| N/A \| N/A Tohoku Region \| N/A \| Japan \| N/A \| N/A	64	0	0	0	NCT01634243	1COMPLETED	2006-05-01	2005-01-01	Otsuka Pharmaceutical Co., Ltd.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	31	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.	null	Epilepsy, Partial	Epilepsy Partial onset seizures Seletracetam	null	1	arm 1: Escalating doses twice daily were to be administered.	[ 0 ]	1	[ 0 ]	intervention 1: * Pharmaceutical form: oral capsules * Concentration: 10 and 50 mg * Route of administration: oral administration	intervention 1: Seletracetam (ucb 44212)	7	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Stanford \| California \| United States \| -122.16608 \| 37.42411 Columbus \| Ohio \| United States \| -82.99879 \| 39.96118 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 Nashvil...	31	0	0	0	NCT00152451	1COMPLETED	2006-05-03	2005-05-19	UCB S.A. - Pharma Sector	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	59	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This trial will evaluate the efficacy and safety of UCB44212 as add-on therapy in subjects with focal epilepsy.	null	Epilepsy, Partial	Epilepsy Partial Onset Seizures Seletracetam Levetiracetam	null	1	arm 1: Escalating doses twice daily were to be administered.	[ 0 ]	1	[ 0 ]	intervention 1: * Pharmaceutical form: oral capsules * Concentration: 2, 10 and 50 mg * Route of administration: oral administration	intervention 1: Seletracetam (UCB44212)	17	Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 St. Petersburg \| Florida \| United States \| -82.67927 \| 27.77086 Springfield \| Illinois \| United States \| -89.64371 \| 39.80172 Wichita \| Kansas \| United States \| -97.33754 \| 37.69224 Detroit \| Michigan...	59	0	0	0	NCT00152503	1COMPLETED	2006-05-12	2005-08-31	UCB Pharma SA	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	224	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The primary purpose of the study is to determine the time-course of recovery to a T4/T1 ratio of 0.9 within 4 minutes after 4.0 mg.kg\^-1 Sugammadex is administered at least 15 minutes after the last administration of rocuronium in a wide range of surgical procedures and anesthetic regimens (routine use). Safety evalua...	null	Anesthesia, General		null	1	arm 1: Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was administered. At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, a...	[ 0 ]	2	[ 0, 0 ]	intervention 1: At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 was administered. intervention 2: Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was requi...	intervention 1: Sugammadex intervention 2: Rocuronium	0	null	197	0	0	0	NCT00298831	1COMPLETED	2006-05-22	2005-10-27	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	189	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	An open-label, multi-center study to establish psoriasis control of moderate to severe plaque psoriasis with Raptiva therapy administered subcutaneously for 24 weeks.	null	Candidates for Systemic Therapy for Psoriasis Psoriasis		null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.	intervention 1: Efalizumab	1	Geneva \| N/A \| Switzerland \| 6.14569 \| 46.20222	189	0	0	0	NCT00287118	1COMPLETED	2006-05-30	2004-10-27	Merck KGaA, Darmstadt, Germany	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	2,615	RANDOMIZED	PARALLEL	1PREVENTION	2DOUBLE	false	0ALL	null	To determine the comparative efficacy and safety of two different doses (75mg day 1 followed by 150 mg day 2-completion, and 110 mg day 1 followed by 220 mg day 2-completion) of dabigatran administered orally (capsules), compared to enoxaparin 30 mg twice a day subcutaneous, in prevention of venous thromboembolism in p...	null	Arthroplasty, Replacement, Knee Thromboembolism		null	3	arm 1: low dose regimen taken once daily arm 2: high dose regimen taken once daily arm 3: 30 mg subcutaneously twice daily	[ 0, 0, 1 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: low dose regimen taken once daily intervention 2: low dose regimen taken once daily intervention 3: high dose regimen taken once daily intervention 4: high dose regimen taken once daily intervention 5: 30 mg subcutaneously twice daily	intervention 1: Dabigatran Dose 1 - day 2 to completion intervention 2: Dabigatran Dose 1 - day 1 intervention 3: Dabigatran Dose 2 - day 2 to completion intervention 4: Dabigatran Dose 2 - day 1 intervention 5: Enoxaparin	94	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Northport \| Alabama \| United States \| -87.57723 \| 33.22901 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Little Rock \| Arkans...	2,596	1	0.000385	0	NCT00152971	1COMPLETED	2006-06-01	2004-11-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0	0	0	0	1	0.000068
[ 5 ]	418	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	An 8-week, open-label trial in 848 subjects at 212 sites to compare time to response in symptoms of anxiety in subjects treated with Niravam™ and a newly prescribed Selective Serotonin Reuptake Inhibitor (SSRI)or Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) to that in subjects treated with a newly prescribed ...	null	Generalized Anxiety Disorder Panic Disorder		null	4	arm 1: Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI arm 2: Panic Disorder: Newly prescribed SSRI or SNRI alone arm 3: Generalized Anxiety Disorder: Niravam plus a newly prescribed SSRI or SNRI arm 4: Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone	[ 0, 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor	intervention 1: Niravam intervention 2: SSRI/SNRI	1	Milwaukee \| Wisconsin \| United States \| -87.90647 \| 43.0389	414	1	0.002415	1	NCT00266409	1COMPLETED	2006-06-01	2005-10-01	UCB Pharma	4INDUSTRY	false	false	false	null	0	0	0	1	0	0.000427
[ 3 ]	5	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Cyclosporine and mycophenolate mofetil may prevent this from happening. PURPOSE:...	Primary objective: * Determine whether allogeneic peripheral blood stem cell transplantation with pre-conditioning low dose total body irradiation and fludarabine followed by cyclosporine and mycophenolate mofetil, when given to elderly patients with acute myeloid leukemia in first complete remission, is sufficiently ...	Leukemia	adult acute myeloid leukemia in remission adult acute myeloid leukemia with t(8;21)(q22;q22) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with 11q23 (MLL) abnormalities	null	1	arm 1: patient conditioning - fludarabine 30 mg/m2 IV over 1 hour Days -4, -3, -2; TBI 6-7 cGy/min Day 0 post-transplant immunosuppression - cyclosporine 6.25 mg/kg bid PO D -3 to +180 (begin taper on D+35); mycophenolate mofetil 15mg/kg bid PO D0 to +27	[ 0 ]	6	[ 2, 0, 0, 0, 3, 4 ]	intervention 1: None intervention 2: None intervention 3: None intervention 4: None intervention 5: None intervention 6: None	intervention 1: therapeutic allogeneic lymphocytes intervention 2: cyclosporine intervention 3: fludarabine intervention 4: mycophenolate mofetil intervention 5: peripheral blood stem cell transplantation intervention 6: radiation therapy	83	Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Duarte \| California \| Un...	5	0	0	0	NCT00053014	6TERMINATED	2006-06-01	2003-04-01	SWOG Cancer Research Network	5NETWORK	false	false	false	null	0	0	0	0	0	0
[ 3 ]	449	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with active SLE disease.	The purpose of this study is to evaluate the safety and efficacy of three different doses of belimumab (1 mg/kg, 4 mg/kg, and 10 mg/kg), administered in addition to standard therapy, compared to placebo plus standard therapy in patients with active SLE disease. Patients were randomly assigned, following stratification ...	Lupus Erythematosus, Systemic	SLE	null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 2, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an add...	intervention 1: Placebo intervention 2: Belimumab 1 mg/kg intervention 3: Belimumab 4 mg/kg intervention 4: Belimumab 10 mg/kg	62	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Paradise Valley \| Arizona \| United States \| -111.94265 \| 33.53115 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 La Jolla \| California \| United States \| -117.2742 \| 32.84727 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Los Angeles...	794	0	0	0	NCT00071487	1COMPLETED	2006-06-01	2003-10-01	Human Genome Sciences Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	862	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.	null	Staphylococcal Skin Infection	staph MRSA cSSSI	null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Telavancin 10 mg/kg/day, IV for up to 14 days. intervention 2: Vancomycin 1 Gm IV q 12 hrs for up to 14 days.	intervention 1: Telavancin intervention 2: Vancomycin	1	National City \| California \| United States \| -117.0992 \| 32.67811	855	0	0	0	NCT00091819	1COMPLETED	2006-06-01	2005-01-01	Cumberland Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	36	RANDOMIZED	PARALLEL	1PREVENTION	4QUADRUPLE	false	0ALL	false	The purpose of this study is to compare the vascular effects of two commonly used blood pressure medications, carvedilol and metoprolol in hypertensive patients with type 2 diabetes.	Carvedilol and metoprolol are two commonly used blood pressure medications that have both been shown to be effective in controlling hypertension. Although in the same drug class, preliminary data have shown that these medications may have different vascular effects. This study will assess which medication is better at ...	Hypertension Type 2 Diabetes Mellitus	beta-blockers endothelial function	null	2	arm 1: Carvedilol, orally, 25 mg, twice daily for five months arm 2: Metoprolol, orally, 200 mg, twice daily for five months.	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 25 mg twice daily for five months. intervention 2: 200 mg twice daily for five months.	intervention 1: Carvedilol intervention 2: Metoprolol	1	Saint Paul \| Minnesota \| United States \| -93.09327 \| 44.94441	36	0	0	0	NCT00123604	1COMPLETED	2006-06-01	2004-06-01	St. Paul Heart Clinic	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	264	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily \[BID\]) versus placebo administered over 6 weeks for the treatment of the signs and symptoms of subjects with active rheumatoid arthritis (RA).	null	Rheumatoid Arthritis	oral JAK inhibitor clinical trial joint diseases anti-Inflammatory agents rheumatic diseases DMARD Antirheumatic Agents Autoimmune Diseases Immune System Diseases	null	4	arm 1: CP 690,550 5 mg BID arm 2: CP 690,550 15 mg BID arm 3: Oral tablets administered at a dose of 30 mg BID for 6 weeks arm 4: Placebo	[ 0, 0, 0, 2 ]	4	[ 0, 0, 0, 10 ]	intervention 1: Oral tablets administered at a dose of 5 mg BID for 6 weeks intervention 2: Oral tablets administered at a dose of 15 mg BID for 6 weeks intervention 3: 30 mg BID for 6 weeks intervention 4: Placebo tablets	intervention 1: CP-690,550 intervention 2: CP-690,550 intervention 3: CP-690,550 intervention 4: Placebo	60	Upland \| California \| United States \| -117.64839 \| 34.09751 Clearwater \| Florida \| United States \| -82.8001 \| 27.96585 Miami \| Florida \| United States \| -80.19366 \| 25.77427 New Port Richey \| Florida \| United States \| -82.71927 \| 28.24418 Ocala \| Florida \| United States \| -82.14009 \| 29.1872 Orlando \| Florida \| United ...	264	0	0	0	NCT00147498	1COMPLETED	2006-06-01	2005-01-01	Pfizer	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	206	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	This was a 22-week, prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study that included a 4-week Baseline Phase at the beginning and a 4-week single-blind placebo Safety Phase at the end of the study.	null	Migraine Prophylaxis		null	2	arm 1: During the Titration Phase, placebo was initiated at a dose of 1.0 mg/day for the first 2 weeks, increased to 1.5 mg/day for the next 2 weeks, and then further increased to 2.0 mg/day for 10 weeks (last 2 weeks of the Titration Phase continuing into the 8-week Maintenance Phase). arm 2: During the Titration Phas...	[ 2, 0 ]	2	[ 0, 10 ]	intervention 1: None intervention 2: None	intervention 1: E2007 intervention 2: Placebo	9	Oceanside \| California \| United States \| -117.37948 \| 33.19587 Santa Monica \| California \| United States \| -118.49138 \| 34.01949 Tampa \| Florida \| United States \| -82.45843 \| 27.94752 West Palm Beach \| Florida \| United States \| -80.05337 \| 26.71534 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Springfield \|...	206	0	0	0	NCT00154063	1COMPLETED	2006-06-01	2005-01-01	Eisai Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	62	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	Comparison of clinical efficacy and safety of levocetirizine in PER continuous versus on demand, measured by evolution of individual symptom scores during 6 months.	null	Rhinitis, Allergic, Perennial	Persistent Allergic Rhinitis HDM Parietaria sneezing rhinorrhea ocular pruritus Rhinasthma inflammatory cells ICAM-1 ATAREAL Xyzal Levocetirizine	null	2	arm 1: 5 mg of Levocetirizine (LCTZ) was taken orally once a day. arm 2: 5 mg of Levocetirizine (LCTZ) was taken whenever needed.	[ 0, 0 ]	1	[ 0 ]	intervention 1: * Pharmaceutical form: Tablet * Concentration: 5 mg * Route of administration: Oral use	intervention 1: Levocetirizine	1	Genova \| N/A \| Italy \| 11.87211 \| 45.21604	62	0	0	0	NCT00160680	1COMPLETED	2006-06-01	2005-03-01	UCB S.A. - Pharma Sector	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 0 ]	45	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	Subjects are scheduled to undergo a Greater Occipital Nerve Block (GONB) as treatment for your chronic daily headache (CDH). GONB has been used for many years in the treatment of headaches. The nerve block is done by injecting a liquid drug through the skin of the back of the head to the area of the greater occipital n...	null	Migraine		null	2	arm 1: Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally. arm 2: Adult patients with CDH, and headache of at least moderate intensity at time o...	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc. intervention 2: lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.	intervention 1: lidocaine, bupivicaine and saline intervention 2: lidocaine plus bupivicaine plus triamcinolone (steroid)	1	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	45	0	0	0	NCT00203294	1COMPLETED	2006-06-01	2005-06-01	Thomas Jefferson University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 0 ]	3	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	0ALL	null	Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The trade name for this drug is Zyprexa®. Olanzapine has not been approved by the FDA for the prevention of migraine and is experimental...	null	Migraine		null	2	arm 1: Olazepam arm 2: None	[ 5, 5 ]	2	[ 0, 0 ]	intervention 1: Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period) intervention 2: Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase...	intervention 1: Olanzapine during first intervention period and placebo during second intervention period intervention 2: Placebo during first intervention period, then olanzapine during second intervention period	1	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	3	0	0	0	NCT00203307	6TERMINATED	2006-06-01	2004-05-01	Thomas Jefferson University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	117	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The intent of this study is to demonstrate the efficacy and safety of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in newly or previously diagnosed CIDP subjects. Eight courses of treatment with either placebo or IGIV-C will occur every 3 weeks. Neurological function will be measu...	110 subjects, 55 per treatment group, with newly or previously diagnosed CIDP defined by INCAT neurophysiological diagnostic criteria will be enrolled into the trial. Patients will not be replaced if they discontinue prematurely.	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	Immunoglobulin G	null	2	arm 1: IGIV-C arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 2 g/kg body weight ideally over 2-4 days . Thereafter, study drug infusion (IGIV-C) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions intervention 2: Albumin 25%, USP diluted with dextrose 5% to a final concentration of 0.1% as an intrav...	intervention 1: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified intervention 2: Albumin (Human) 25%, United States Pharmacopeia (USP)	32	New Haven \| Connecticut \| United States \| -72.92816 \| 41.30815 St Louis \| Missouri \| United States \| -90.19789 \| 38.62727 New York \| New York \| United States \| -74.00597 \| 40.71427 Winston-Salem \| North Carolina \| United States \| -80.24422 \| 36.09986 Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995 Dallas \| Texas...	208	0	0	0	NCT00220740	1COMPLETED	2006-06-01	2004-04-01	Grifols Therapeutics LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	82	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The objective of this trial is to evaluate safety and efficacy of rotigotine nasal spray (SPM 952) in a single dose application scheme. Subjects will undergo a 2 - 28 days screening period in which eligibility criteria will be checked. Subjects will then be hospitalized for one night. In the morning of the next day, s...	The objective of this trial is to evaluate safety and efficacy of rotigotine nasal spray (SPM 952)in a single dose application scheme. Subjects will undergo a 2-28 days screening period in which eligibility criteria will be checked. Subjects will then be hospitalized for one night. In the morning of the next day, subje...	Parkinson's Disease	Rotigotine Rotigotine nasal spray Efficacy, safety and tolerability Parkinson's disease	null	5	arm 1: Placebo nasal spray 1 - 4 puffs arm 2: Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine) arm 3: Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine) arm 4: Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine) arm 5: Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)	[ 2, 0, 0, 0, 0 ]	2	[ 0, 10 ]	intervention 1: Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries intervention 2: placebo nasal spray 1, 2 3, and 4 puffs	intervention 1: Rotigotine nasal spray intervention 2: Placebo	0	null	82	0	0	0	NCT00296192	1COMPLETED	2006-06-01	2006-02-01	UCB Pharma	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	49	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This study evaluates the safety and efficacy of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Efficacy outcomes include evaluation...	Participants with NHL and MM who have undergone prior cyto-reductive chemotherapy, are to be autologously transplanted, and meet the inclusion/exclusion criteria are eligible to enter the study. The only change to the standard of care is the addition of plerixafor to a granulocyte colony-stimulating factor (G-CSF) mobi...	Lymphoma, Non-Hodgkin Multiple Myeloma	Non-Hodgkin's Lymphoma Multiple Myeloma Stem cell mobilization	null	2	arm 1: Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for u...	[ 0, 0 ]	1	[ 0 ]	intervention 1: Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and recei...	intervention 1: G-CSF Plus Plerixafor	8	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Loa Angeles \| California \| United States \| N/A \| N/A Maywood \| Illinois \| United States \| -87.84312 \| 41.8792 Iowa City \| Iowa \| United States \| -91.53017 \| 41.66113 Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997 Rochester \| Minnesota \| Unite...	49	0	0	0	NCT00322491	1COMPLETED	2006-06-01	2004-03-01	Genzyme, a Sanofi Company	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	456	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	null	This study compares of the safety and efficacy of intravenous iron vs oral iron in the treatment of anemia secondary to heavy uterine bleeding	This is an open-label, randomized, Phase III, active-control, study of the efficacy and safety of IV iron vs oral iron in patients with anemia secondary to heavy uterine bleeding.	Anemia	anemia heavy uterine bleeding menorrhagia Anemia secondary to heavy uterine bleeding	null	2	arm 1: Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered arm 2: 325 mg tablets TID on Days 0 through Day 42	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered intervention 2: 325 mg tablets TID on Days 0 through Day 42	intervention 1: Ferric Carboxymaltose (FCM) intervention 2: Ferrous Sulfate tablets	1	Norristown \| Pennsylvania \| United States \| -75.3399 \| 40.1215	456	0	0	0	NCT00395993	1COMPLETED	2006-06-01	2005-05-01	American Regent, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.